Document text
FINAL RE
PORT
Test Facility Study No. 185350
Sponsor Reference No. ALC- NC-0552
A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle -mRNA
Formulation Containing ALC -0315 and ALC-0159 Following
Intramuscular Administration in Wistar Han Rats
TEST FAC
ILITY:
SPONSOR:
Acuitas Therapeutics Inc.
6190 Agronomy Road, Suite 402
Vancouver, British Columbia
V6T 1Z3 Canada
Page 1 of 77
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-0013962
Page 2
Test Facility Study No: 185350
TABLE OF CONTENTS
1 COMPLIANCE STATEMENT ................................................................................ 6
2 QUALITY ASSURANCE STATEMENT ............................................................... 7
3 RESPONSIBLE PERSONNEL ................................................................................ 8
4 SUMMARY ................................................................................................................ 9
5 INTRODUCTION .................................................................................................... 11
5.1 Study Location .......................................................................................................... 11
5.2 Study Dates ............................................................................................................... 11
5.3 Archiving ................................................................................................................... 12
6 EXPERIMENTAL PROCEDURE ......................................................................... 12
6.1 Test Item ................................................................................................................... 12
6.2 Other Materials ........................................................................................................ 13
6.3 Animals and Husbandry .......................................................................................... 14
6.4 Specific Activity ........................................................................................................ 14
6.5 Dose Formulation ..................................................................................................... 14
6.6 Dose Administration and Determination ............................................................... 15
6.7 Collection of Biological Samples ............................................................................. 15
6.8 Sample Storage ......................................................................................................... 16
6.9 Preparation of Samples for Total Radioactivity Analysis .................................... 16
6.9.1 Dose Formulation ..................................................................................................... 16
6.9.2 Blood and Plasma ..................................................................................................... 16
6.9.3 Tissues ....................................................................................................................... 16
6.9.4 Urine, Faeces and Cage Wash ................................................................................. 17
6.10 Quantification of Radioactivity ............................................................................... 17
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013963
Page 3
Test Facility Study No: 185350
6.10.1 Liquid Scintillation Counting ................................................................................. 17
6.10.2 Data Presentation ..................................................................................................... 17
6.11 Protocol Deviations .................................................................................................. 18
7 RESULTS ................................................................................................................. 19
7.1 Clinical Observations ............................................................................................... 19
7.2 Body Weights ............................................................................................................ 19
7.3 Tissue Distribution Following Intramuscular Administration ............................ 19
8 CONCLUSIONS ...................................................................................................... 22
9 TABLES .................................................................................................................... 23
10 APPENDICES .......................................................................................................... 28
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013964
Page 4
Test Facility Study No: 185350
Table 1 LIST OF TABLES
Mean (Sexes-Combined) Concentration and Recovery of Total
Radioactivity in Whole Blood, Plasma and Tissues Following Single
Intramuscular Administration of [3H] -08-A 01-C01 to Wistar Han Rats ......... 23
Table 2 Mean Concentration of Total Radioactivity in Whole Blood, Plasma
and Tissues Following Single Intramuscular Administration of
[3H]-08-A 01-C01 to Wistar Han Rats .............................................................. 25
Table 3 Mean Recovery of Total Radioactivity in Tissues Following Single
Intramuscular Administration of [3H]-08-A 01-C01 to Wistar Han Rats ......... 27
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013965
Page 5
Test Facility Study No: 185350
LIST OF APPENDICES
Appendix 1 Certificates of Analysis for [3H]-08-A 01 -C01 and [3H]-C HE ......................... 28
Appendix 2 Individual Animal Dosing Summary ................................................................ 30
Appendix 3 Urine and Faeces Sample Weights ................................................................... 33
Appendix 4 Individual Male Concentration Data ................................................................ 36
Appendix 5 Individual Female Concentration Data ............................................................. 43
Appendix 6 Individual Male Recovery Data ........................................................................ 50
Appendix 7 Individual Female Recovery Data .................................................................... 57
Appendix 8 Individual Male 100 µg mRNA data ................................................................ 64
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013966
Page 6
Test Facility Study No: 185350
1 COMPLIANCE STATEMENT
Study Title: A Tissue Distribution Study of a [3H]-Labelled Lipid Nanoparticle -mRNA
Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular
Administration in Wistar Han Rats
GLP regulations are not applicable to studies of this nature therefore no claim of GLP compliance is made. Nevertheless, as Study Director, I confirm that this study was conducted in a GLP compliant facility and that the practices and procedures adopted during its conduct were consistent with the OECD Principles of Good Laboratory Practice as incorporated into the United Kingdom Statutory Instrument f or GLP.
The study was conducted according to the procedures herein described and this report represents a true and accurate record of the results obtained.
Study Director
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-0013967
Page 7
Test Facility Study No: 185350
2 QUALITY ASSURANCE ST ATEMENT
Study Title: A Tiss ue Distribution Study of a [3H]-Labelled Lipid Nanoparticle -mRNA
Formulation Containing ALC-0315 and ALC-0159 Following Intramuscular
Administration in Wistar Han Rats
This study has not been subjected to any study specific Quality Assurance procedures.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013968
Page 8
Test Facility Study No: 185350
3 RESPONSIBLE PERSONNEL
Study Director:
Sponsor Representative:
Test Facility Management:
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (4)
(b) (6)
(b) (4)
FDA-CBER-2021-5683-0013969
Page 9
Test Facility Study No: 185350
4 SUMMARY
The test item, 08 -A01-C01, is an aqueous dispersion of lipid nanoparticles (LNP), compr ised
of a proprietary mixture of lipid components (including ALC-0315, ALC-0159,
distearoylphosphatidylcholine, and cholesterol) and mRNA. The mRNA encodes a model protein (luciferase) and is not pharmacologically active. The test item contains trace amoun ts
of radiolabelled [Cholesteryl-1,2-
3H(N)] -Cholesteryl Hexadecyl Ether ([3H]-CHE), a non-
exchangeable, non-metabolisable lipid marker used to monitor the disposition of the lipid nanoparticles (containing encapsulated mRNA). Once intracellular, the [
3H]-CHE does not
recirculate and therefore allows assessment of distribution of the particles .
The objectives of this study were to:
1. Characterise the disposition of 08- A01-C01 containing a radiolabelled lipid marker in
male and female Wistar Han rats following a single intramuscular administration .
2. Determine the concentration and content of radioactivity in blood, plasma and tissues
of rats (expressed as μg lipid eq/ mL (or per g for tissue ), and % administered ( injected
dose) /tissue, where appropriate) .
Wistar Han rats (21 male and 21 female ) each received a single i ntramuscular dose of
[3H]-08-A01-C01 at a target mRNA total dose of 50 µg/animal (1.29 mg/animal total lipid
dose). The content and concentration of total radioactivity in blood, plasma and tissues were determined at pre-defined time points following administration.
Whole blood and ti ssue samples were collected at 0.25 1, 2, 4, 8, 24 and 48 hours post-dose
(three animals/sex/timepoint) and plasma was subsequently separated from blood by
centrifugation. The concentration of total radioactivity was measured by liquid scintillation counting (LSC).
Following i ntramuscular administration of [
3H]-08-A01-C01 to male and female Wistar Han
rats at a target dose level of 50 µg/animal (1.29 mg/animal total lipid dose), the greatest mean
concentration was found remaining in the injection site at each time point in both sexes. Outside the injection site , low levels of radioactivity were detected in most tissues, with the
greatest levels in plasma observed 1-4 hours post-dose. Over 48 hours, [
3H]-08-A01-C01
distributed mainly to liver, adrenal glands , spleen and ovaries , with maximum c oncentrations
observed at 8-48 hours post-dose. Total recovery (% of injected dose) of [3H]-08-A01-C01
outside the injection site was greatest in the liver (up to 21.5%) and was much less in spleen
(≤1.1%), adrenal glands ( ≤0.1%) and ovaries ( ≤0.1%). The me an concentrations and tissue
distribution pattern were broadly similar between the sexes.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013970
Page 10
Test Facility Study No: 185350
Blood:plasma ratios were ge nerally between 0.5 -0.6, indicating that the majority of the total
radioactivity is associated with the plasma frac tion and that [3H]-08-A01-C01 does not
undergo appreciable accumulation in red blood cells.
In conclusion, the distribution of [
3H]-08-A01-C01 (monitoring the [3H]-CHE lipid label) in
blood, plasma and selected tissues was determined in male and female Wistar Han rats over 48 hours after a single intramuscular inj ection at 50 µg mRNA/animal (1.29 mg/animal lipid
dose). The concentration s of [
3H]-08-A01-C01 were greatest in the injection site at all time
points, with levels peaking in the plasma by 1 -4 hours post-dose and distribution mainly into
liver, adrenal glands, spleen and ovaries over 48 hours. Total recovery of radioactivity outside of the injection site was greatest in the liver, with much lower total recovery in spleen, and very little recovery in adrenals glands and ovaries. The mean plasma, blood and tissue concentrations and tissue distribution patterns were broadly similar between the sexes and
[
3H]-08-A01-C01 did not associate with red blood cells.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013971
Page 11
Test Facility Study No: 185350
5 INTRODUCTION
The objectives of this study were to:
1. Characterise the disposition of 08- A01-C01 containing a radiolabelled lipid marker in
male and female Wistar Han rats following a single intramuscular administration
2. Determine the concentration and content of radioactivity in blood, plasma and tissues of rats (express ed as μg lipid eq/ g (or per mL for plasma ) and % injected dose/tissue,
where appropriate)
The Wistar Han rat was chosen as the animal model for this study as it is an accepted rodent species for preclinical toxicity testing by regulatory agencies and has been used in all regulatory toxicology studies by the Sponsor. The study was designed to be appropriate for submission to regulatory authorities. However, it is recognised that no detailed test guidelines for the conduct of drug distribution and pharmacok inetic studies are currently available.
Initially , 21 male rats were dosed at 100 µg mRNA/animal. Some adverse clinical signs were
observed after approximately 24 hours post-dose and a subsequent review of the data showed concentrations were well detected in tissues. After discussions with the Sponsor, the target dose level was lowered to 50 µg mRNA/animal by amendment for the remainder of the study. Reference is made to the 100 µg mRNA /animal group in some sections of the report, however, the results are not discussed.
5.1 Study Location
The study was carried out at
according to Protocol
No. 185350 and Amendments 1 and 2.
5.2 Study Dates
The study was conducted according to the following timetable:
Study Initiation: 16 July 2020
Experimental Start Date: 17 July 2020
Experimental Completion Date: 24 September 2020
Study Completion Date: See compliance page for date of Study Director’s signature.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-0013972
Page 12
Test Facility Study No: 185350
5.3 Archiving
All raw data generated and recorded during this study will be stored in the Scientific Archive
of for 2 years after issue of the final report. After
the 2 -year period the Sponsor will be consulted regarding the disposal, transfer, or continued
storage of the raw data. Electronic data generated by the Test Facility were archived as noted above, except reporting files stored on Shared Document Management System (SDMS), which were archived at the The original signed copy of the final report will be stored indefinitely in the Scientific Archive of The residual [
3H]-08-A01-C01 dose (appr oximately 5 MBq) will be retained and stored in a
fridge set to maintain 4°C at Biological samples generated during the course of this study were held deep frozen until issue of the final report. will contact the Sponsor to discuss the fate of the samples
(disposal, return or retain at ) on issue of the final report. Samples will be
disposed of unless receives written instruction regarding shipment of the
samples to the Sp onsor or continued storage at
6 EXPERIMENTAL PROCEDURE
6.1 Test Item
Identification: [
3H]-08-A01-C01
Supplier: Acuitas Therapeutics Inc
Lot Number: NC-0552-1
Expiration Date: July 7, 2021
Physical Description: White to off-white, homogenous, opalescent liquid; no foreign
particles
Concentration 1.0 mg/mL (mRNA):
Radioactive 0.864 mCi/mL, 1,900,000 dpm/µL
Concentration
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-0013973
Page 13
Test Facility Study No: 185350
Concentration 25.7 mg/mL
(Total Lipid)
Molecular weight Not applicable for LNP
Purity: 94%
Radiochemical >97%
Purity
Specific Activity (mRNA): 0.864 mCi/mg (32.0 MBq/mg)
Correction Factor None
Storage Conditions: Frozen (-60°C to -90°C)
The test item contains trace amounts of radiolabelled [Cholesteryl-1,2-
3H(N)] -Cholesteryl
Hexadecyl Ether ([3H]-CHE ), a non- exchangeable, non -metabolisable lipid marker used to
monitor the disposition of the lipid nanoparticles (containing encapsulated mRNA). Per the
manufacturer’s information, the radiochemical purity of [3H]-CHE was found to be >97% and
the rate of decomposition is initially 2% for 6 months from the date of purification
(16 December 2019). No radiochemical purity assessments were made as part of this study.
The Certificates of Analysis fo r [3H]-08-A 01-C01 and [3H]-C HE are p resented in Appendix 1.
6.2 Other Materials
AquaSafe 500 Plus liquid scintillation fluid was obtained from Zinsser Inc.
Monophase® was used in conjunction with the Perkin Elmer Model 307 Automatic Sample Oxidiser and was supplied by Perkin Elmer Life Science and Analytical Instruments Inc, UK.
Spec- Chec
™-3H used to estimate efficiencies of combustion was also obtained from Perkin
Elmer Life Science and Analytical Instruments Inc, UK .
All other materials and chemicals used were of analytical grade where available and supplied by standard commercial suppliers.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013974
Page 14
Test Facility Study No: 185350
6.3 Animals and Husbandry
Forty -two male and 21 female Wistar Han rats (8-11 weeks and body weight 179-270 g at the
time of dosing) were used in the study and were supplied by The animals
were acclimatised to the experimental unit for at least 5 days prior to use on the study.
During the acclimatisation periods, the animals were closely observed by the animal technicians to ensure that they were in good health and suitable for inclusion in the study.
During the study period the animals were closely observed twice daily by the animal technicians to ensure that they were in good health. During the study period, the rats were housed in groups in polycarbonate and stai nless steel
cages with wire mesh floors. Animals used for excretion collection were housed singly in all-
glass metabolism cages for the separate collection of urine and faeces.
A standard laboratory diet of known formulation (SDS Rat and Rat Maintenance Diet No.1,
Special Diet Services, 1 Stepfield, Witham, Essex) and domestic mains tap water were available ad libitum .
Holding and study areas had automatic control of light cycles and temperature. Automatic 12 hours light and 12 hours dark. Ranges of temperature and humidity measured during the study were 21-23ºC and 44-67%, respectively , with the exception of 31 July 2020 where the
room temperature reached a maximum of 25ºC.
6.4 Specific Activity
The specific activ ity value of 1.24 MBq/mg lipid ( as calculated from the
0.864 mCi/mg mRNA s pecific activity value supplied and converted to per mg lipid) was
used to calculate the amount of [
3H]-08-A01-C01 dispensed in the dose formulation.
6.5 Dose Formulation
[
3H]-08-A01-C01 was provided in PBS/sucrose buffer at the required dose concentration
(1 mg mRNA/mL). No dilutions were therefore required. Four dose formulation vials were
provided (3 x 1.5 mL and 1 x 1.2 mL).
The appropriate number of vials for each dosing occasion were defrosted for at least 30 minutes prior to dosing. Prior to use, each vial was inverted 3 times to mix. Once dosing was complete, each vial was stor ed in a fridge within 4 hours of removal from the -80°C
freezer.
The r adioactive concentration of the supplied dose formulation was determined by the
removal of triplicate aliquots (50 μL) prior to and after the first dosing occasion . Appropriate
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (4)
FDA-CBER-2021-5683-0013975
Page 15
Test Facility Study No: 185350
dilutions of each aliquot were prepared in distilled water and duplicate aliquots of each
dilution were analysed by liquid scintillation counting (LSC ).
The radioactive concentration determined by LSC was within 10% of the target value
provided in the supplied Certificate of Analysis and was used in the dose determination calculations.
6.6 Dose Administration and Determination
Each animal received a single (one site) i ntramuscular administration of [
3H]-08-A01-C01 at
either 50 or 100 μL volume for the 50 and 100 μg mRNA/animal dose groups, respectively (target doses of 1.29 or 2.57 mg total lipid/animal, respectively ).
The actual dos e received by e ach animal w as de termined w ith reference to t he dose
concentration, the volume of dose administered an d the specifi c activity of [3H]-08-A01- C01
in the formulated dose. Any undosed residue was also taken in to account. T he actual dose
received by each animal is documented in Appendix 2.
6.7 Collection of Biological Samples
Three male and three female rats were sacrificed at the following times:
0.25, 1, 2, 4, 8, 24 and 48 hours post dose
From each animal, a terminal blood sample ( ca. 5-10 mL) was collected by cardiac puncture
into heparinised tubes. A portion ( ca. 0.5 mL) was retained and plasma separated from the
remainder of each sample by centrifugation (3000 rpm for 10 minutes in a centrifuge set to
maintain a temperature of 4°C). Blood cells were discarded.
The following tissues were collected (where relevant for sex) :
Adipose tissue Ovaries
Adrenal glands Pancreas
Bladder Pituitary gland
Bone (femur) Prostate
Bone marrow (femur) Salivary glands
Brain Skin
Eyes Muscle
Heart Small intestine
Injection site Spinal cord
Kidneys Spleen
Large intestine Stomach
Liver Testes
Lung Thymus
Lymph node (mandibular) Thyroid
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013976
Page 16
Test Facility Study No: 185350
Lymph node (mesenteric) Uterus
Additionally, for animals 043M, 045M, 046M, 048M, 051M, 052M, 055M and 058M, the
tibia/fibula bone was also collected but not analysed (refer to Section 6.11).
6.8 Sample Storage
Samples not analysed immediately were stored frozen in a freezer set to maintain a
temperature of -20°C until taken for analysis, with the exception of urine and faeces samples
which were stored at - 80°C. After analysis, samples were returned to storage in a freezer set
to maintain a temperature of -20°C.
Samples of cage wash, dose determinations and dose residues were stored at room
temperature prior to and following analysis. These samples were discarded at the Study
Director’s discretion following acceptance of the study results.
6.9 Preparation of Samples for Total Radioactivity Analysis
Volumes or weights of all samples were measured where appropriate
6.9.1 Dose For mulation
Duplicate aliquots (0.1 mL) of each dilution of the dose formulation were diluted with water
and dissolved in scintillation fluid (Aquasafe 500 Plus, Zinsser Inc.) and analysed directly by
liquid scintillation counting.
6.9.2 Blood and Plasma
Duplicate weighed aliquots of whole blood (2 x ca . 0.15 g) were taken and then combusted
using a Perkin Elmer Model 307 Sample Oxidiser. The resultant 3H2O generated was
collected by absorption in Monophase® (15 mL).
Duplicate aliquots (100 μL) of plasma were allowed to air dry, diluted with water and
dissolved in scintillation fluid (Aquasafe 500 Plus, Zinsser Inc.) and analysed directly by
LSC.
6.9.3 Tissues
Tissue samples were finely chopped with scissors and duplicate, where appropriate, portions were combusted using a Perkin Elmer Model 307 Sample Oxidiser. Smaller tissues were aliquoted directly. The resultant
3H2O generated was collected by absorption in
Monophase® S (15 mL).
Combustion of standards showed that recovery efficiencies were in excess of 95% throughout.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013977
Page 17
Test Facility Study No: 185350
6.9.4 Urine, Faeces and Cage Wash
Urine, f aeces and cage wash s amples were collected but not a nalysed for total radioactivity.
Urine and faeces s ampl e weights were taken prior to storage. U rine and faeces s amples
were retained at -80°C for possible analysis of specific lipids by LC-MS/MS conducted and
reported separately. The sample weights are presented in Appendix 3.
6.10 Quantification of Radioactivity
6.10.1 Liquid Scintillation Counting
All samples prepared in scintillation fluid were subjected to liquid scintillation counting for
5 min, together with representative blank samples, using a Liquid Scintillation Analyser with
automatic quench correction by an external standard method. Prior to analysis, samples were
allowed to stabilise with regard to light and temperature. Self-normalisation and calibration
(SNC) were conducted once a day. An unquenched tritium standard was used to initially calibrate the system to obtain optimal performance b y adjusting the voltage on the photo-
multiplier tubes.
Representative blank sample values were subtracted from sample count rates
to give net disintegrations per minute (dpm) per sample. A limit of reliable measurement of
30 counts per minute (cpm) above background was instituted in these laboratories. Any
results aris ing from data below the limit of reliable measurement were noted in the Results
section of the report. Sample repeat analysis were in accordance with Standard Operating Procedures.
6.10.2 Data P resentation
Levels of radioactivity in all samples w ere quantified by LSC and the data captured into
DEBRA® management software, Version 5.7 (LabLogic Ltd, UK). Plasma, blood and tissues concentrations of radioactivity in dpm/g and mass eq/g were calculat ed based on the measured
specific activity (1.24 MBq/mg lipid) of radiolabel led test item in the dose formulation.
Individual and mean data were tabulated. The following information was reported:
•Radioactive content in tissues where a total organ weight is applicable was calculated
as % administered (injected) dose
•Radioactive content in tissues, whole blood and plasma as μg equiv/g (or mL).
•Blood/plasma ratio
Data presented in results tables are computer generated in DEBRA and rounded appropriately
for inclusion in the report. As a consequence, calculation of individual and mean values from
data presented will, in some instances, yield slight differences from the results presented.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013978
Page 18
Test Facility Study No: 185350
6.11 Protocol Deviations
Due to the unavailabili ty of rats within specification at the rat
supplier used in this study was Envigo, UK, deviating from Section 11 of the Protocol. In the
opinion of the Study Director this had no impact on the study outcome since the correct age and strain of rats were used on this study. In error, t ibia/fibula bone were collected at necropsy for animals 043M, 045M, 046M, 048M,
051M, 052M, 055M, and 058M instead of femur bone, deviating from Section 14.1 of the Protocol. Once noticed, the femur bone was retrieved from the residual carcass stored in t he
-20°C freezer pending disposal and analysed after discussions with the Sponsor. The results
appeared similar to the other animals in each timepoint and therefore this had no impact on the study outcome.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (4)
FDA-CBER-2021-5683-0013979
Page 19
Test Facility Study No: 185350
7 RESULTS
7.1 Clinical Observations
In the 100 µg mRNA male group, approximately 24 h f ollowing administration, animal 021M
was noted to have decreased activity, ungroomed, brown staining on muzzle and irregular
respiration. A decrease in bodyweight was noted in all remaining animal s (approximately
16 g, equivalent to ca. 7% reduction of bodyweight ) and food hoppers appeared untouched.
By approximately 30 hours post-dose, animal 021M was also piloerect, hunched, and was hypersensitive to noise stimulus. Animal 021M was humanely killed and the diagnostic necropsy carried out showed one find ing in the liver (prominent lobular architecture) .
Additionally, animals 019M and 020M were hunched and piloerect from approximately 30 h post-dose onwards.
In the 50 µg mRNA male group, following administration and for the duration of the study,
no adve rse effects were noted in any animal.
In the 50 µg mRNA female group, approximately 30 h following administration, animal 042F was noted to have decreased activity, and irregular respiration. At 48 h post dose animal 042F was additionally hunched and pil oerect.
7.2 Body Weights
At the time of dosing, body weights were in the range of 217-270 g ( males) and 179-224 g
(females).
7.3 Tissue Distribution Following Intramuscular Administration
The mean ( sex com bined) concentration a nd recover y of total radioactivity in whole blood,
pla
sma, inj ection site and tissues f ol lowing a single int r amuscular administration of [3H]- 08-
A01-C01 to W istar H an rats at a target dose level of 50 µg mRNA/animal (1.29 mg/animal
lipid)
is presented in Table 1. The mean concentration of total radioactivity in whole blood,
plasma, inj ection site and tissues f ol lowing a single int r amuscular administration of
[3H]-08-A 01
-C01 to m ale and f emale Wistar Han rats at a target dose level of 50 µg mRNA/
animal (1.29 mg /animal
lipid) is presented in Table 2 . The mean recovery in male and
female individual tissues is presented in
Table 3 .
Individual male and female concentration d ata is presented in Appendix 4 and Appendix 5,
respectively. Individual male and
female re covery data i s presented in Appendix 6 and
Appendix 7, respectively. The male 100 µg data is presented in Appendix 8 .
When analysing the injection site, t here was often high inter- animal variability in
concentration and % injected dose values at each time point. This may have been due to
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013980
Page 20
Test Facility Study No: 185350
difficulty in collecting the entirety of this sample since the total area that the injected bolus
dose migrated to within the muscle was not visible. When dosing the male 50 µg mRNA
group, the injection site was circl ed using a marker pen to help aid dissection of the injection
area. The overall in jection site concentrations and % dose values were higher in males than in
females . Since concentrations in other tissues were broadly similar between the sexes , it is
likely that the higher injection site values in males were a result of its more consistent
identification and collection in males .
Following a single intramuscular administration of [3H]-08-A01-C01, the greatest mean tissue
concentration and, in most instances, % of injected dose was found remaining in the injection
site at each time point in both sexes. The injection site mean concentration and equivalent % dose values are presented in the tab le below.
Timepoint
(h) Injection site
(µg equiv lipid/g) Injection site
(% dose)
Male Female Male Female
0.25 219.940 36.566 32.887 6.815
1 587.670 199.950 68.829 36.411
2 529.210 93.144 39.053 24.094
4 619.850 56.227 47.710 9.056
8 299.590 125.930 18.731 24.993
24 267.170 122.540 31.957 26.295
48 268.770 61.088 32.823 16.426
The highest mean recovery of total radioactivity observed was 68.8% of the administered dose at 1 -hour post- dose in males .
Low levels of radioactivity were detected in most tissues from the first time point (0.25 h),
with the greatest level found circulating in plasma between 1-4 hours post-dose. The plasma
and blood mean concentrations and blood:plasma ratios are presented in the table below.
Timepoint
(h) Blood
(µg equiv lipid/g ) Plasma
(µg equiv lipid/mL ) Blood:plasma
ratio
Male Female Male Female Male Female
0.25 3.003 0.936 6.035 1.894 0.48 1.15
1 2.809 5.928 5.379 10.884 0.49 0.54
2 4.028 6.773 8.714 9.091 0.46 0.64
4 3.400 2.698 8.755 4.251 0.42 0.60
8 2.000 0.628 3.573 1.147 0.56 0.55
24 1.274 0.544 2.621 0.945 0.49 0.57
48 0.535 0.305 1.085 0.524 0.50 0.58
Mean plasma concentrations peaked by 4 h ours post-dose in males (8.755 µg equiv lipid/mL)
and by 1 hour post-dose in females (10.884 µg equiv lipi d/mL) , before steadily decreasing.
Concentrations were higher in plasma than in blood, with mean blood:plasma ratios generally
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013981
Page 21
Test Facility Study No: 185350
ca. 0.5-0.6, indicating that the majority of the total radioactivity is associated with the plasma
fraction.
Over 48 hours, [3H]-08- A01-C01 distributed from the injection site to most tissues , with the
majority of tissues exhibiting low levels of radioactivity . The h ighest mean concentrations
observed, and the equivalent % dose, are presented in the tables below.
Timepoint
(h) Values expressed as µg equiv lipid/g )
Liver Spleen Adrenal glands Ovaries
Male Female Male Female Male Female Female
0.25 1.151 0.323 0.354 º0.313 0.302 º0.240 º0.104
1 4.006 5.244 2.140 2.801 0.580 2.388 1.339
2 9.574 12.370 5.255 10.213 1.206 4.232 1.638
4 18.525 14.569 8.945 11.646 2.569 3.206 2.341
8 27.916 25.172 24.434 19.747 6.387 7.218 3.088
24 23.360 15.119 22.819 17.341 19.948 7.595 5.240
48 18.164 30.411 19.550 27.155 21.476 14.942 12.261
=Mean includes results calculated from data l es s than 30 cpm above background
Timepoint
(h) Liver Spleen Adrenal glands Ovaries
Male Female Male Female Male Female Female
0.25 0.995 0.209 0.014 º0.011 0.001 º0.001 º0.001
1 2.834 2.907 0.087 0.098 0.002 0.012 0.009
2 7.629 7.030 0.232 0.418 0.005 0.015 0.008
4 15.027 8.699 0.351 0.419 0.012 0.018 0.016
8 21.519 14.580 1.118 0.845 0.026 0.043 0.025
24 19.901 10.977 0.957 0.685 0.083 0.049 0.037
48 13.953 18.357 0.914 1.146 0.104 0.108 0.095
=Mean includes results calculated from data less than 30 cpm above background
Maximum concentrations (C
max) in liver and spleen were observed at 8 hours post-dose in
males and 48 hours post dose in females, but were broadly similar and appeared to plateau at 8 hours post-dose when considering variability. The greatest mean concentration outside the injection site was observed in the liver, with values of 27.916 µg equiv lipid /g (equivalent to
21.5 % dose) in males and 30.411 µg equiv lipid/g (equivalent to 18.4 % dose) in females. In
the spleen the highest concentrations were 24.434 µg equiv lipid/g in males and 27.155 µg equiv lipid/g (equivalent to 1.1% dose in both sexes).
In the adrenal glands and ovaries, the highest mean concentrations were observed at 48 hours
post-dose. The highest mean concentrations in the adrenal glands were 21.476 and 14.942 µg equiv lipid/g in males and females, respectively (equivalent to 0.1% dose in both
sexes ). The highest mean ovaries concentration was 12.261 µg equiv lipid/g (equivalent to
0.1 % dose).
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013982
Page 22
Test Facility Study No: 185350
8 CONCLUSIONS
In conclusion, the distribution of [3H]-08-A01-C01 (monitoring the [3H]-CHE lipid label) in
blood, plasma and selected tissues was determined in male and female Wistar Han rats over
48 hours after a single intramuscular injection at 50 µg mRNA/animal (1.29 mg/animal lipid dose). The concentrations of [
3H]-08-A01-C01 were greatest in the injection site at all time
points, with levels peaking in the plasma by 1-4 hours post-dose and distribution mainly into liver, adrenal glands, spleen and ovaries over 48 hours. Total recovery of radioactivity outside of the injection site was greatest in the liver, with much lower total recovery in spleen, and very little recovery in adrenals glands and ovaries. The mean plasma, blood and tissue concentrations and tissue dis tribution pattern s were broadly similar between the sexes and
[
3H]-08-A01-C01 did not associate with red blood cells.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013983
Page 23
Test Facility Study No: 185350
9 TABLES
Table 1 Mean (Sexes -Combined) Concentration and Recovery of Total Radioactivity in Whole Blood,
Plasma and Tissues Following Single Intram uscular Administration of [3H]-08-A01-C01 to Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as total lipid concentration ( µg lipid equiv/g (mL)) and % of administered dose
Sample Total Lipid Concentrat ion (µg lipid equiv/g ( or mL)) % of Administered Dose
0.25 min 1 h 2 h 4 h 8 h 24 h 48 h 0.25 min 1 h 2 h 4 h 8 h 24 h 48 h
Adipose tissue 0.057 0.100 0.126 0.128 0.093 0.084 0.181 - - - - - - -
Adrenal glands 0.271 1.484 2.719 2.888 6.803 13.772 18.20 9 0.001 0.007 0.010 0.015 0.035 0.066 0.106
Bladder 0.041 0.130 0.146 0.167 0.148 0.247 0.365 0.000 0.001 0.001 0.001 0.001 0.002 0.002
Bone (femur) 0.091 0.195 0.266 0.276 0.340 0.342 0.687 - - - - - - -
Bone marrow (femur) 0.479 0.960 1.237 1.236 1.836 2.492 3.771 - - - - - - -
Brain 0.045 0.100 0.138 0.115 0.073 0.069 0.068 0.007 0.013 0.020 0.016 0.011 0.010 0.009
Eyes 0.010 0.035 0.052 0.067 0.059 0.091 0.112 0.000 0.001 0.001 0.002 0.002 0.002 0.003
Heart 0.282 1.029 1.402 0.987 0.790 0.451 0.546 0.018 0.056 0.084 0.060 0.042 0.027 0.030
Injection site 128.253 393.810 311.177 338.039 212.760 194.855 164.929 19.851 52.620 31.574 28.383 21.862 29.126 24.625
Kidneys 0.391 1.161 2.046 0.924 0.590 0.426 0.425 0.050 0.124 0.211 0.109 0.075 0.054 0.057
Large intestine 0.013 0.048 0.093 0.287 0.649 1.104 1.338 0.008 0.025 0.065 0.192 0.405 0.692 0.762
Liver 0.737 4.625 10.972 16.547 26.544 19.240 24.288 0.602 2.871 7.330 11.863 18.050 15.439 16.155
Lung 0.492 1.210 1.834 1.497 1.151 1.039 1.093 0.052 0.101 0.178 0.169 0.122 0.101 0.101
Lymph node ( man) 0.064 0.189 0.290 0.408 0.534 0.554 0.727 - - - - - - -
Lymph node ( mes) 0.050 0.146 0.530 0.489 0.689 0.985 1.366 - - - - - - -
Muscle 0.021 0.061 0.084 0.103 0.096 0.095 0.192 - - - - - - -
Ovarie s (females) 0.104 1.339 1.638 2.341 3.088 5.240 12.261 0.001 0.009 0.008 0.016 0.025 0.037 0.095
Pancreas 0.081 0.207 0.414 0.380 0.294 0.358 0.599 0.003 0.007 0.014 0.015 0.015 0.011 0.019
Pituitary gland 0.339 0.645 0.868 0.854 0.405 0.478 0.694 0.000 0.001 0.001 0.001 0.000 0.000 0.001
Prostate (males) 0.061 0.091 0.128 0.157 0.150 0.183 0.170 0.001 0.001 0.002 0.003 0.003 0.004 0.003
Salivary glands 0.084 0.193 0.255 0.220 0.135 0.170 0.264 0.003 0.007 0.008 0.008 0.005 0.006 0.009
Skin 0.013 0.208 0.159 0.145 0.119 0.157 0.253 - - - - - - -
- =Partial tissue taken therefore not applicable
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013984
Page 24
Test Facility Study No: 185350
Table 1 Mean (Sexes -Combined) Concentration of Total Radioactivity in Whole Blood, Plasma and
(Continued) Tissues Following Single Intramuscular Administration of [3H]-08-A01-C01 to Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as total lipid concentration ( µg lipid equiv/g (mL)) and % of administered dose
Sample Total Lipid Concentration (µg lipid equiv/ g (or mL)) % of Administered Dose
0.25 min 1 h 2 h 4 h 8 h 24 h 48 h 0.25 min 1 h 2 h 4 h 8 h 24 h 48 h
Small intestine 0.030 0.221 0.476 0.879 1.279 1.302 1.472 0.024 0.130 0.319 0.543 0.776 0.906 0.835
Spinal cord 0.043 0.097 0.169 0.250 0.106 0.085 0.112 0.001 0.002 0.002 0.003 0.001 0.001 0.001
Spleen 0.334 2.471 7.734 10.296 22.091 20.080 23.353 0.013 0.093 0.325 0.385 0.982 0.821 1.030
Stomach 0.017 0.065 0.115 0.144 0.268 0.152 0.215 0.006 0.019 0.034 0.030 0.040 0.037 0.039
Testes (males) 0.031 0.042 0.079 0.129 0.146 0.304 0.320 0.007 0.010 0.017 0.030 0.034 0.074 0.074
Thymus 0.088 0.243 0.340 0.335 0.196 0.207 0.331 0.004 0.007 0.010 0.012 0.008 0.007 0.008
Thyroid 0.155 0.536 0.842 0.851 0.544 0.578 1.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001
Uterus (females) 0.043 0.203 0.305 0.140 0.287 0.289 0.456 0.002 0.011 0.015 0.008 0.016 0.018 0.022
Whole blood 1.970 4.369 5.401 3.049 1.314 0.909 0.420 - - - - - - -
Plasma 3.965 8.132 8.903 6.503 2.360 1.783 0.805 - - - - - - -
Blood:plas ma ratio 0.815 0.515 0.550 0.510 0.555 0.530 0.540 - - - - - - -
- =Partial tissue taken therefore not applicable/not applicable
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013985
Page 25
Test Facility Study No: 185350
Table 2 Mean Concentration of Tot al Radioactivity in Whole Blood, Plasma and Tissues Following Single
Intra muscular Administration of [3H]-08-A01-C01 to Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 0.25 min 1 h 2 h 4 h 8 h 24 h 48 h
Male Female Male Female Male Female Male Female Male Female Male Female Male Female
Adipose tissue 0.040 º0.073 0.050 0.149 0.070 0.182 0.093 0.163 0.116 0.069 0.126 0.042 0.129 0.232
Adrenal glands 0.302 º0.240 0.580 2.388 1.206 4.232 2.569 3.206 6.387 7.218 19.948 7.595 21.476 14.942
Bladder 0.049 º0.033 0.095 0.165 0.137 0.155 0.227 0.106 0.211 0.085 0.323 0.171 0.340 0.389
Bone (femur) 0.126 0.056 0.148 0.241 0.235 0.296 0.335 0.217 0.502 0.177 0.504 0.180 0.520 0.854
Bone marrow (femur) 0.761 º0.196 0.910 1.010 1.136 1.337 1.557 0.915 2.397 1.274 3.579 1.405 3.690 3.851
Brain 0.073 º0.016 0.083 0.117 0.143 0.133 0.155 0.075 0.101 0.045 0.090 0.047 0.083 0.052
Eyes 0.014 º0.006 0.027 0.043 0.046 0.058 0.095 0.038 0.088 0.030 0.129 0.052 0.127 0.097
Heart 0.419 º0.144 0.631 1.426 1.122 1.682 1.049 0.925 1.189 0.391 0.583 0.318 0.672 0.420
Injection site 219.940 36.566 587.670 199.950 529.210 93.144 619.850 56.227 299.590 125.930 267.170 122.540 268.770 61.088
Kidneys 0.511 0.271 0.630 1.692 1.124 2.967 1.033 0.814 0.837 0.342 0.504 0.348 0.482 0.368
Large intestine 0.017 º0.008 0.031 0.065 0.080 0.106 0.350 0.224 0.690 0.608 1.741 0.466 1.426 1.249
Liver 1.151 0.323 4.006 5.244 9.574 12.370 18.525 14.569 27.916 25.172 23.360 15.119 18.164 30.411
Lung 0.737 0.247 0.845 1.574 1.594 2.074 1.772 1.222 1.674 0.628 1.316 0.762 1.288 0.898
Lymph node ( man) 0.090 º0.038 0.154 0.223 0.217 0.362 0.424 0.391 0.695 0.372 0.744 0.363 0.820 0.633
Lymph node ( mes) 0.052 º0.048 0.095 0.196 0.229 0.831 0.441 0.536 0.649 0.729 1.106 0.863 1.057 1.675
Muscle º0.029 0.012 0.039 0.082 0.067 0.100 0.075 0.130 0.101 0.091 0.098 0.092 0.280 0.104
Ovaries (females) - º0.104 - 1.339 - 1.638 - 2.341 - 3.088 - 5.240 - 12.261
Pancreas 0.125 0.037 0.153 0.261 0.423 0.404 0.361 0.398 0.349 0.239 0.396 0.320 0.587 0.611
Pituitary gl and 0.537 º0.141 0.446 0.844 0.781 0.955 1.249 0.458 0.669 0.141 0.656 0.300 0.543 0.845
Prostate (males) 0.061 - 0.091 - 0.128 - 0.157 - 0.150 - 0.183 - 0.170 -
Salivary glands 0.114 º0.054 0.148 0.237 0.214 0.295 0.270 0.169 0.176 0.094 0.243 0.096 0.297 0.231
Skin º0.016 0.010 0.028 0.387 0.054 0.263 0.085 0.204 0.122 0.116 0.195 0.118 0.209 0.297
°=Mean includes results calculated from data less than 30 cpm above background
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013986
Page 26
Test Facility Study No: 185350
Table 2 Mean Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues Following Single
(Continued) Intramuscular Administration of [3H]-08-A01-C01 to Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 0.25 min 1 h 2 h 4 h 8 h 24 h 48 h
Male Female Male Female Male Female Male Female Male Female Male Female Male Female
Small intestine 0.038 º0.021 0.194 0.247 0.471 0.481 0.919 0.838 1.525 1.033 1.878 0.726 1.630 1.314
Spinal cord 0.061 º0.024 0.072 0.122 0.166 0.172 0.375 0.124 0.168 0.044 0.121 0.048 0.162 0.062
Spleen 0.354 º0.313 2.140 2.801 5.255 10.213 8.945 11.646 24.434 19.747 22.819 17.341 19.550 27.155
Stomach 0.018 º0.015 0.039 0.091 0.104 0.126 0.186 0.101 0.410 0.126 0.222 0.081 0.235 0.195
Testes (males) 0.031 - 0.042 - 0.079 - 0.129 - 0.146 - 0.304 - 0.320 -
Thymus 0.106 º0.069 0.187 0.298 0.220 0.459 0.461 0.209 0.292 0.100 0.255 0.159 0.296 0.366
Thyroid 0.217 º0.093 0.391 0.680 0.575 1.109 1.097 0.604 0.781 0.307 0.820 0.335 1.344 0.655
Uterus (females) - º0.043 - 0.203 - 0.305 - 0.140 - 0.287 - 0.289 - 0.456
Whole Blood 3.003 0.936 2.809 5.928 4.028 6.773 3.400 2.698 2.000 0.628 1.274 0.544 0.535 0.305
Plasma 6.035 1.894 5.379 10.884 8.714 9.091 8.755 4.251 3.573 1.147 2.621 0.945 1.085 0.524
Blood:pla sma ratio 0.48 1.15 0.49 0.54 0.46 0.64 0.42 0.60 0.56 0.55 0.49 0.57 0.50 0.58
°=Mean includes results calculated from data less than 30 cpm above background
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013987
Page 27
Test Facility Study No: 185350
Table 3 Mean Recovery of Total Radioactivity in Tissues Following Single Intramuscular Administration
of [3H]-08-A01-C01 to Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal Results expressed as % administered dose
Sample 0.25 min 1 h 2 h 4 h 8 h 24 h 48 h
Male Female Male Female Male Female Male Female Male Female Male Female Male Female
Adrenal glands 0.001 º0.001 0.002 0.012 0.005 0.015 0.012 0.018 0.026 0.043 0.083 0.049 0.104 0.108
Bladder 0.000 º0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.002 0.000 0.002 0.001 0.002 0.002
Brain 0.011 º0.002 0.010 0.016 0.021 0.019 0.021 0.011 0.014 0.007 0.012 0.007 0.011 0.007
Eyes 0.000 º0.000 0.000 0.001 0.001 0.001 0.002 0.001 0.002 0.001 0.002 0.001 0.003 0.002
Heart 0.028 º0.008 0.032 0.079 0.065 0.102 0.067 0.052 0.061 0.022 0.035 0.018 0.039 0.020
Injection site 32.88 7 6.815 68.829 36.411 39.053 24.094 47.710 9.056 18.731 24.993 31.957 26.295 32.823 16.426
Kidneys 0.069 0.030 0.077 0.171 0.149 0.272 0.136 0.082 0.109 0.040 0.068 0.039 0.071 0.042
Large intestine 0.011 º0.004 0.018 0.032 0.054 0.075 0.236 0.148 0.463 0.346 1.091 0.293 0.810 0.714
Liver 0.995 0.209 2.834 2.907 7.629 7.030 15.027 8.699 21.519 14.580 19.901 10.977 13.953 18.357
Lung 0.082 0.022 0.085 0.117 0.189 0.167 0.226 0.112 0.180 0.064 0.136 0.065 0.131 0.070
Ovaries (females) - º0.001 - 0.009 - 0.008 - 0.016 - 0.025 - 0.037 - 0.095
Pancreas 0.005 0.001 0.006 0.008 0.015 0.012 0.013 0.017 0.014 0.016 0.013 0.009 0.015 0.023
Pituitary gland 0.000 º0.000 0.000 0.001 0.000 0.001 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.001
Prostate (males) 0.001 - 0.001 - 0.002 - 0.003 - 0.003 - 0.004 - 0.003 -
Salivary glands 0.004 º0.002 0.005 0.008 0.007 0.009 0.009 0.006 0.007 0.003 0.008 0.003 0.010 0.007
Small intestine 0.032 º0.015 0.124 0.135 0.353 0.285 0.623 0.462 0.972 0.580 1.275 0.536 0.971 0.698
Spinal cord 0.001 º0.000 0.001 0.002 0.001 0.002 0.003 0.002 0.001 0.001 0.001 0.001 0.001 0.001
Spleen 0.014 º0.011 0.087 0.098 0.232 0.418 0.351 0.419 1.118 0.845 0.957 0.685 0.914 1.146
Stomach 0.008 º0.003 0.016 0.022 0.033 0.035 0.037 0.022 0.055 0.024 0.054 0.020 0.049 0.029
Testes (males) 0.007 - 0.010 - 0.017 - 0.030 - 0.034 - 0.074 - 0.074 -
Thymus 0.005 º0.002 0.006 0.008 0.008 0.012 0.018 0.006 0.012 0.003 0.009 0.004 0.008 0.007
Thyroid 0.000 º0.000 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.000 0.001 0.000 0.001 0.001
Uterus (females) - º0.002 - 0.011 - 0.015 - 0.008 - 0.016 - 0.018 - 0.022
°=Mean includes results calculated from data less than 30 cpm above backgroun d
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013988
Page 28
Test Facility Study No: 185350
10 APPENDICES
Appendix 1 Certificates of Analysis for [3H]-08-A01-C01 and [3H]-CHE
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
(b) (6)
(b) (6)
FDA-CBER-2021-5683-0013989
Page 29
Test Facility Study No: 185350
Appendix 1 Certificates of Analysis for [3H]-08-A01-C01 and [3H]-CHE
(continued)
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013990
Page 30
Test Facility Study No: 185350
Appendix 2 Individual Animal Dosing Summary
Males
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Animal ID Body
weight (g) Dose Received
mg mRNA mg lipid MBq
043M 270 0.0514 1.32 1.63
044M 264 0.0518 1.33 1.65
045M 244 0.0521 1.34 1.66
046M 263 0.0525 1.35 1.68
047M 232 0.0514 1.32 1.64
048M 228 0.0525 1.35 1.67
049M 259 0.0514 1.32 1.64
050M 249 0.0518 1.33 1.66
051M 257 0.0533 1.37 1.70
052M 258 0.0521 1.34 1.66
053M 249 0.0529 1.36 1.69
054M 235 0.0525 1.35 1.68
055M 247 0.0502 1.29 1.60
056M 256 0.0514 1.32 1.64
057M 266 0.0521 1.34 1.66
058M 263 0.0521 1.34 1.66
059M 243 0.0525 1.35 1.67
060M 248 0.0518 1.33 1.65
061M 240 0.0521 1.34 1.66
062M 259 0.0521 1.34 1.66
063M 238 0.0521 1.34 1.66
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013991
Page 31
Test Facility Study No: 185350
Appendix 2 Individual Animal Dosing Summary
(continued)
Females
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Animal ID Body
weight (g) Dose Received
mg mRNA mg lipid MBq
022F 215 0.0521 1.34 1.66
023F 206 0.0529 1.36 1.68
024F 206 0.0514 1.32 1.64
025F 212 0.0533 1.37 1.70
026F 213 0.0525 1.35 1.68
027F 207 0.0529 1.36 1.69
028F 198 0.0529 1.36 1.68
029F 208 0.0529 1.36 1.69
030F 214 0.0518 1.33 1.64
031F 204 0.0537 1.38 1.71
032F 207 0.0533 1.37 1.70
033F 209 0.0521 1.34 1.66
034F 224 0.051 0 1.31 1.62
035F 179 0.0482 1.24 1.53
036F 211 0.0467 1.20 1.49
037F 205 0.0506 1.30 1.61
038F 225 0.0502 1.29 1.60
039F 213 0.0525 1.35 1.67
040F 199 0.0533 1.37 1.69
041F 218 0.0529 1.36 1.69
042F 193 0.0533 1.37 1.70
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013992
Page 32
Test Facility Study No: 185350
Appendix 2 Individual Animal Dosing Summary
(continued)
Males
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal
Animal ID Body
weight (g) Dose Received
mg mRNA mg lipid MBq
001M 240 0.104 2.66 3.30
002M 243 0.106 2.73 3.38
003M 277 0.107 2.74 3.40
004M 247 0.106 2.72 3.37
005M 243 0.107 2.76 3.42
006M 237 0.107 2.74 3.39
007M 245 0.107 2.75 3.41
008M 237 0.106 2.73 3.39
009M 248 0.106 2.73 3.39
010M 227 0.101 2.60 3.22
011M 267 0.105 2.71 3.36
012M 237 0.106 2.72 3.37
013M 241 0.105 2.69 3.34
014M 264 0.107 2.76 3.42
015M 264 0.105 2.71 3.36
043M 241 0.106 2.73 3.39
017M 252 0.106 2.73 3.39
018M 263 0.105 2.70 3.35
019M 248 0.106 2.72 3.37
020M 246 0.106 2.73 3.39
021M 217 0.107 2.75 3.41
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013993
Page 33
Test Facility Study No: 185350
Appendix 3 Urine and Faeces Sample Weights
Males
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal Results expressed in g
Sample Timepoint 061M 062M 063M
Urine Pre-dose 6.860 18.617 14.228
6 h 6.139 8.101 8.153
24 h 21.208 29.766 40.276
48 h 28.317 28.566 36.902
Faeces Pre-dose 11.324 7.893 6.070
24 h 4.716 14.327 8.659
48 h 6.968 8.398 7.007
.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013994
Page 34
Test Facility Study No: 185350
Appendix 3 Urine and Faeces Sample Weights
(continued)
Females
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal Results expressed in g
Sample Timepoint 040F 041F 042F
Urine Pre-dose 3.963 9.453 7.513
6 h 4.844 5.664 9.719
24 h 20.736 29.176 21.294
48 h 30.371 33.928 23.141
Faeces Pre-dose 6.110 2.679 6.010
24 h 8.887 9.193 5.619
48 h 4.565 6.139 4.834
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013995
Page 35
Test Facility Study No: 185350
Appendix 3 Urine and Faeces Sample Weights
(continued)
Males Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal
Results expressed in g
Sample Timepoint 019M 020M 021M
Urine Pre-dose 7.519 4.094 13.159
6 h 8.883 8.835 10.517
24 h 29.916 22.983 12.664
48 h 37.860 35.653 *6.931
Faeces Pre-dose 9.491 9.292 4.882
24 h 11.197 14.005 8.769
48 h 6.950 8.229 *2.449
Note that for animal 021M the collection period was
approximately 24 -31 h.
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013996
Page 36
Test Facility Study No: 185350
Appendix 4 Indivi dual Male Concentration Data
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 0.25 min Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lip id/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 043M 044M 045M Mean SD
Adipose tissue 0.056 0.045 0.019 0.040 0.019
Adrenal glands 0.380 0.480 0.046 0.302 0.227
Bladder 0.096 0.045 0.007 0.049 0.045
Bone (femur) 0.172 0.085 0.119 0.126 0.044
Bone marrow (femur) 0.775 0.326 1.182 0.761 0.428
Brain 0.093 0.092 0.033 0.073 0.034
Eyes 0.025 0.013 0.005 0.014 0.010
Heart 0.710 0.474 0.074 0.419 0.322
Injection site 436.090 159.310 64.429 219.940 193.100
Kidneys 0.808 0.600 0.123 0.511 0.351
Large intestine 0.020 0.027 0.003 0.017 0.012
Liver 2.035 1.226 0.193 1.151 0.923
Lung 1.050 0.826 0.334 0.737 0.366
Lymph node (Man) 0.152 0.069 0.049 0.090 0.055
Lymph node (Mes) 0.087 0.054 0.016 0.052 0.036
Muscle 0.049 0.035 *0.003 º0.029 º0.024
Pancreas 0.156 0.201 0.019 0.125 0.095
Pituitary gland 0.962 0.535 0.115 0.537 0.424
Prostate 0.098 0.074 0.012 0.061 0.044
Salivary glands 0.169 0.145 0.028 0.114 0.076
Skin 0.030 0.015 *0.002 º0.016 º0.014
Small intestine 0.064 0.043 0.008 0.038 0.028
Spinal cord 0.108 0.063 0.013 0.061 0.047
Spleen 0.519 0.450 0.094 0.354 0.228
Stomach 0.022 0.027 0.005 0.018 0.012
Testes 0.053 0.036 0.006 0.031 0.024
Thymus 0.119 0.169 0.030 0.106 0.071
Thyroid 0.292 0.307 0.053 0.217 0.142
Whole Blood 5.631 2.526 0.852 3.003 2.425
Plasma 9.854 6.519 1.732 6.035 4.083
Blood:plasma ratio 0.57 0.39 0.49 0.48 0.09
*=Results calculated from data less than 30 cpm above background
°=Mean includes results calculated from data less than 30 cpm above backg round
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013997
Page 37
Test Facility Study No: 185350
Appendix 4 Individual Male Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues 1 hour Following Single Intramuscular Administration of
[
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 046M 047M 048M Mean SD
Adipose tissue 0.037 0.073 0.040 0.050 0.020
Adrenal glands 0.293 0.647 0.800 0.580 0.260
Bladder 0.111 0.087 0.088 0.095 0.013
Bone (femur) 0.115 0.085 0.246 0.148 0.085
Bone marrow (femur) 0.561 1.150 1.021 0.910 0.310
Brain 0.033 0.108 0.107 0.083 0.043
Eyes 0.014 0.019 0.049 0.027 0.019
Heart 0.266 0.780 0.847 0.631 0.318
Injection site 503.490 593.230 666.280 587.670 81.536
Kidneys 0.322 0.710 0.857 0.630 0.276
Large intestine 0.026 0.032 0.037 0.031 0.005
Liver 2.667 3.571 5.780 4.006 1.602
Lung 0.428 1.203 0.903 0.845 0.391
Lymph node (Man) 0.151 0.166 0.145 0.154 0.011
Lymph node (Mes) 0.076 0.100 0.109 0.095 0.017
Muscle 0.030 0.036 0.050 0.039 0.010
Pancreas 0.076 0.189 0.193 0.153 0.067
Pituitary gland 0.202 0.502 0.634 0.446 0.221
Prostate 0.063 0.105 0.105 0.091 0.024
Salivary glands 0.084 0.151 0.208 0.148 0.062
Skin 0.020 0.027 0.039 0.028 0.010
Small inte stine 0.144 0.214 0.223 0.194 0.043
Spinal cord 0.062 0.070 0.084 0.072 0.011
Spleen 3.314 1.388 1.720 2.140 1.029
Stomach 0.024 0.043 0.049 0.039 0.013
Testes 0.026 0.041 0.057 0.042 0.015
Thymus 0.201 0.133 0.226 0.187 0.048
Thyroid 0.126 0.599 0.448 0.391 0.241
Whole Blood 0.873 4.534 3.018 2.809 1.840
Plasma 2.937 6.047 7.153 5.379 2.186
Blood:plasma ratio 0.30 0.75 0.42 0.49 0.23
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013998
Page 38
Test Facility Study No: 185350
Appendix 4 Individual Male Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues 2 hours Following Single Intramuscular Administration of
[
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 049M 050M 051M Mean SD
Adipose tissue 0.084 0.034 0.090 0.070 0.031
Adrenal glands 1.809 0.584 1.226 1.206 0.613
Bladder 0.152 0.080 0.179 0.137 0.051
Bone (femur) 0.250 0.180 0.273 0.235 0.048
Bone marrow (femur) 1.526 0.559 1.323 1.136 0.510
Brain 0.220 0.088 0.121 0.143 0.069
Eyes 0.036 0.023 0.077 0.046 0.028
Heart 1.782 0.682 0.901 1.122 0.582
Injection site 445.930 1052.800 88.843 529.210 487.370
Kidneys 1.467 0.785 1.120 1.124 0.341
Large intestine 0.074 0.056 0.109 0.080 0.027
Liver 12.023 5.816 10.885 9.574 3.304
Lung 2.397 0.968 1.419 1.594 0.730
Lymph node (Man) 0.328 0.112 0.210 0.217 0.108
Lymph node (Mes) 0.312 0.180 0.194 0.229 0.073
Muscle 0.083 0.060 0.057 0.067 0.014
Pancreas 0.296 0.179 0.792 0.423 0.325
Pituitary gland 1.175 0.405 0.764 0.781 0.385
Prostate 0.150 0.095 0.139 0.128 0.029
Salivary glands 0.279 0.113 0.251 0.214 0.089
Skin 0.083 0.032 0.048 0.054 0.026
Small intestine 0.455 0.458 0.500 0.471 0.025
Spinal cord 0.184 0.150 0.163 0.166 0.017
Spleen 6.771 2.590 6.403 5.255 2.315
Stomach 0.121 0.059 0.133 0.104 0.040
Testes 0.120 0.039 0.077 0.079 0.040
Thymus 0.248 0.146 0.265 0.220 0.065
Thyroid 0.749 0.361 0.615 0.575 0.197
Whole Blood 4.913 2.788 4.384 4.028 1.106
Plasma 10.623 6.177 9.341 8.714 2.288
Blood:plasma ratio 0.46 0.45 0.47 0.46 0.01
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0013999
Page 39
Test Facility Study No: 185350
Appendix 4 Individual Male Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues 4 h ours Following Single Intramuscular Administration of
[
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 052M 053M 054M Mean SD
Adipose tissue 0.062 0.092 0.124 0.093 0.031
Adrenal glands 2.252 1.999 3.456 2.569 0.779
Bladder 0.207 0.239 0.234 0.227 0.017
Bone (femur) 0.264 0.234 0.506 0.335 0.149
Bone marrow (femur) 1.318 1.364 1.987 1.557 0.374
Brain 0.136 0.112 0.217 0.155 0.055
Eyes 0.084 0.133 0.067 0.095 0.034
Heart 0.993 0.669 1.484 1.049 0.411
Injection site 445.970 1001.000 412.620 619.850 330.480
Kidneys 0.967 0.737 1.395 1.033 0.334
Large intestine 0.413 0.311 0.327 0.350 0.055
Liver 14.739 16.391 24.445 18.525 5.193
Lung 2.047 1.003 2.265 1.772 0.675
Lymph node (Man) 0.283 0.564 0.426 0.424 0.140
Lymph node (Mes) 0.287 0.258 0.780 0.441 0.293
Muscle 0.064 0.057 0.104 0.075 0.025
Pancreas 0.277 0.413 0.393 0.361 0.073
Pituitary gland 0.933 2.418 0.397 1.249 1.047
Prostate 0.161 0.121 0.190 0.157 0.035
Salivary glands 0.232 0.197 0.380 0.270 0.097
Skin 0.073 0.052 0.131 0.085 0.041
Small intestine 0.822 0.698 1.235 0.919 0.281
Spinal cord 0.193 0.745 0.188 0.375 0.320
Spleen 6.146 11.159 9.529 8.945 2.557
Stomach 0.324 0.058 0.176 0.186 0.134
Testes 0.105 0.098 0.185 0.129 0.049
Thymus 0.210 0.371 0.800 0.461 0.305
Thyroid 1.055 1.301 0.936 1.097 0.186
Whole Blood 3.547 2.519 4.133 3.400 0.817
Plasma 8.820 4.802 12.644 8.755 3.922
Blood:plasma ratio 0.40 0.52 0.33 0.42 0.10
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014000
Page 40
Test Facility Study No: 185350
Appendix 4 Individual Male Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues 8 h ours Following Single Intramuscular Administration of
[
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL )
Sample 055M 056M 057M Mean SD
Adipose tissue 0.076 0.163 0.109 0.116 0.044
Adrenal glands 4.440 4.886 9.835 6.387 2.995
Bladder N.S. 0.198 0.224 0.211 N.A.
Bone (femur) 0.510 0.355 0.639 0.502 0.142
Bone marrow (femur) 3.050 1.943 2.199 2.397 0.579
Brain 0.105 0.096 0.103 0.101 0.005
Eyes N.S. 0.071 0.104 0.088 N.A.
Heart 1.418 1.008 1.142 1.189 0.209
Injection site 181.620 497.270 219.870 299.590 172.260
Kidneys 0.934 0.795 0.783 0.837 0.084
Large intestine 0.735 0.665 0.672 0.690 0.039
Liver 23.158 22.178 38.412 27.916 9.103
Lung 1.679 1.643 1.701 1.674 0.029
Lymph node (Man) 0.432 1.053 0.601 0.695 0.321
Lymph node (Mes) 0.444 0.609 0.892 0.649 0.226
Muscle 0.082 0.096 0.127 0.101 0.023
Pancreas 0.352 0.418 0.276 0.349 0.071
Pituitary gland 0.635 0.477 0.894 0.669 0.211
Prostate 0.184 0.127 0.139 0.150 0.030
Salivary glands 0.170 0.157 0.202 0.176 0.023
Skin 0.138 0.111 0.117 0.122 0.014
Small intestine 1.423 1.518 1.634 1.525 0.106
Spinal cord 0.146 0.119 0.239 0.168 0.063
Splee n 21.122 24.073 28.107 24.434 3.507
Stomach 0.345 0.107 0.777 0.410 0.340
Testes 0.153 0.107 0.179 0.146 0.037
Thymus 0.317 0.278 0.282 0.292 0.021
Thyroid 0.940 0.611 0.792 0.781 0.165
Whole Blood 2.215 1.968 1.817 2.000 0.201
Plasma 3.978 3.465 3.275 3.573 0.364
Blood:plasma ratio 0.56 0.57 0.55 0.56 0.01
N.S. = No sample due to oxidiser failure
N.A. = Not applicable
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014001
Page 41
Test Facility Study No: 185350
Appendix 4 Individual Male Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues 24 hours Following Single Intramuscular Administration of
[
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 058M 059M 060M Mean SD
Adipose tis sue 0.079 0.116 0.182 0.126 0.053
Adrenal glands 10.795 21.060 27.988 19.948 8.650
Bladder 0.211 0.394 0.365 0.323 0.099
Bone (femur) 0.456 0.408 0.649 0.504 0.127
Bone marrow (femur) 2.286 3.625 4.824 3.579 1.270
Brain 0.049 0.099 0.124 0.090 0.038
Eyes 0.098 0.113 0.178 0.129 0.042
Heart 0.640 0.590 0.520 0.583 0.060
Injection site 178.010 330.550 292.960 267.170 79.471
Kidneys 0.522 0.407 0.584 0.504 0.090
Large intestine 0.592 1.611 3.019 1.741 1.219
Liver 17.750 21.966 30.365 23.360 6.422
Lung 0.942 1.334 1.672 1.316 0.365
Lymph node (Man) 0.577 0.689 0.965 0.744 0.200
Lymph node (Mes) 0.905 1.040 1.373 1.106 0.241
Muscle 0.092 0.068 0.133 0.098 0.033
Pancreas 0.294 0.382 0.513 0.396 0.110
Pituitary gland 0.489 0.768 0.711 0.656 0.147
Prostate 0.150 0.183 0.215 0.183 0.032
Salivary glands 0.168 0.243 0.317 0.243 0.075
Skin 0.134 0.166 0.287 0.195 0.081
Small intestine 0.971 1.994 2.670 1.878 0.855
Spinal cord 0.091 0.144 0.127 0.121 0.027
Spleen 19.140 15.796 33.523 22.819 9.419
Stomach 0.110 0.168 0.386 0.222 0.145
Testes 0.234 0.286 0.392 0.304 0.080
Thymus 0.163 0.235 0.368 0.255 0.104
Thyroid 0.721 0.660 1.081 0.820 0.228
Whole Blood 1.473 1.237 1.112 1.274 0.183
Plasma 2.584 2.935 2.345 2.621 0.297
Blood:plasma ratio 0.57 0.42 0.47 0.49 0.08
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014002
Page 42
Test Facility Study No: 185350
Appendix 4 Individual Male Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues 48 h ours Following Single Intramuscular Administration of
[
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 061M 062M 063M Mean SD
Adipose tissue 0.104 0.162 0.121 0.129 0.030
Adrenal glands 13.913 35.091 15.424 21.476 11.815
Bladder 0.274 0.447 0.298 0.340 0.094
Bone (femur) 0.344 0.577 0.639 0.520 0.155
Bone marrow (femur) 2.566 5.049 3.455 3.690 1.258
Brain 0.051 0.112 0.087 0.083 0.031
Eyes 0.100 0.121 0.160 0.127 0.031
Heart 0.418 0.955 0.642 0.672 0.270
Injection site 292.370 196.9 10 317.030 268.770 63.446
Kidneys 0.309 0.673 0.463 0.482 0.182
Large intestine 0.998 1.235 2.045 1.426 0.549
Liver 17.734 20.580 16.177 18.164 2.233
Lung 0.809 1.885 1.170 1.288 0.548
Lymph node (Man) 0.728 1.078 0.656 0.820 0.226
Lymph node (Mes) 0.924 1.620 0.626 1.057 0.510
Muscle 0.078 0.115 0.647 0.280 0.318
Pancreas 0.291 0.506 0.964 0.587 0.344
Pituitary gland 0.431 0.610 0.588 0.543 0.098
Prostate 0.110 0.265 0.135 0.170 0.083
Salivary glands 0.286 0.370 0.234 0.297 0.069
Skin 0.177 0.267 0.183 0.209 0.051
Small intestine 1.178 2.030 1.681 1.630 0.428
Spinal cord 0.089 0.129 0.267 0.162 0.093
Spleen 12.073 25.689 20.887 19.550 6.906
Stomach 0.122 0.315 0.268 0.235 0.101
Testes 0.214 0.471 0.275 0.320 0.134
Thymus 0.226 0.362 0.299 0.296 0.068
Thyroid 0.830 1.797 1.406 1.344 0.486
Whole Blood 0.594 0.473 0.536 0.535 0.060
Plasma 1.021 1.003 1.230 1.085 0.126
Blood:plasma ratio 0.58 0.47 0.44 0.50 0.08
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014003
Page 43
Test Facility Study No: 185350
Appendix 5 Individual Fem ale Concentration Data
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 0.25 min Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Female Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 022F 023FA 024F Mean SD
Adipose tissue 0.203 *0.002 0.015 º0.073 º0.113
Adrenal glands 0.578 *0.000 0.143 º0.240 º0.301
Bladder 0.050 *0.000 0.048 º0.033 º0.029
Bone (femur) 0.146 0.003 0.019 0.056 0.079
Bone marrow (femur) N.S. 0.264 *0.128 º0.196 N.A.
Brain 0.036 *0.002 0.011 º0.016 º0.018
Eyes 0.015 *0.000 0.004 º0.006 º0.008
Injection site 27.519 77.480 4.697 36.566 37.225
Heart 0.310 *0.001 0.121 º0.144 º0.156
Kidneys 0.544 0.126 0.143 0.271 0.236
Large intestine 0.019 *0.001 0.004 º0.008 º0.01 0
Liver 0.635 0.018 0.316 0.323 0.309
Lung 0.550 0.012 0.177 0.247 0.275
Lymph node (Man) 0.088 *0.000 0.025 º0.038 º0.045
Lymph node (Mes) 0.127 *0.000 0.018 º0.048 º0.069
Muscle 0.024 0.006 0.007 0.012 0.010
Ovaries 0.206 *0.000 0.106 º0.104 º0.103
Pancreas 0.072 0.008 0.030 0.037 0.033
Pituitary gland 0.310 *0.000 0.113 º0.141 º0.157
Salivary glands 0.133 *0.000 0.028 º0.054 º0.070
Skin 0.018 0.004 0.009 0.010 0.007
Small intestine 0.051 *0.001 0.010 º0.021 º0.026
Spinal cord 0.057 *0.000 0.016 º0.024 º0.029
Spleen 0.366 *0.004 0.570 º0.313 º0.287
Stomach 0.032 *0.001 0.013 º0.015 º0.016
Thymus 0.159 *0.003 0.047 º0.069 º0.080
Thyroid 0.181 *0.000 0.097 º0.093 º0.091
Uterus 0.090 *0.000 0.037 º0.043 º0.045
Whole Blood 2.016 0.013 0.778 0.936 1.011
Plasma 4.189 0.005 1.487 1.894 2.121
Blood:plasma ratio 0.48 2.43 0.52 1.15 1.12
N.S. = No sample due to analysis error (the bone marrow was not able to be removed from the
bone since the bone was initially crushed for analysis)
A = Anima l 023F appeared to have a slow distribution compared with the other animals
*=Results calculated from data less than 30 cpm above background
°=Mean includes results calculated from data less than 30 cpm above background
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014004
Page 44
Test Facility Study No: 185350
Appendix 5 Individual Fem ale Concen tration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 1 hour Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Female Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/An imal
Results expressed as µg lipid equiv/g (mL)
Sample 025F 026F 027F Mean SD
Adipose tissue 0.145 0.234 0.069 0.149 0.083
Adrenal glands 1.779 2.131 3.254 2.388 0.770
Bladder 0.123 0.206 0.166 0.165 0.042
Bone (femur) 0.216 0.285 0.223 0.241 0.038
Bone marrow (femur) 0.886 1.219 0.926 1.010 0.182
Brain 0.096 0.139 0.115 0.117 0.022
Eyes 0.052 0.052 0.027 0.043 0.015
Heart 1.273 1.884 1.120 1.426 0.404
Injection site 31.021 202.720 366.100 199.950 167.560
Kidneys 1.568 2.396 1.112 1.692 0.651
Large intestine 0.060 0.065 0.070 0.065 0.005
Liver 6.342 4.717 4.674 5.244 0.951
Lung 1.455 1.954 1.313 1.574 0.336
Lymph node (Man) 0.226 0.266 0.176 0.223 0.045
Lymph node (Mes) 0.207 0.226 0.155 0.196 0.037
Muscle 0.080 0.093 0.072 0.082 0.011
Ovaries 1.630 1.650 0.736 1.339 0.522
Pancreas 0.208 0.343 0.234 0.261 0.072
Pituitary gland 0.607 1.114 0.810 0.844 0.255
Salivary glands 0.245 0.327 0.140 0.237 0.094
Skin 0.056 0.956 0.148 0.387 0.495
Small intestine 0.281 0.223 0.235 0.247 0.031
Spinal cord 0.111 0.119 0.137 0.122 0.013
Spleen 2.423 2.626 3.355 2.801 0.490
Stomach 0.085 0.118 0.070 0.091 0.025
Thymus 0.248 0.483 0.164 0.298 0.165
Thyroid 0.510 0.997 0.533 0.680 0.275
Uterus 0.194 0.251 0.164 0.203 0.044
Whole Blood 5.057 8.484 4.243 5.928 2.251
Plasma 9.655 14.318 8.680 10.884 3.014
Blood:plasma ratio 0.52 0.59 0.49 0.54 0.05
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014005
Page 45
Test Facility Study No: 185350
Appendix 5 Individual Female Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 2 hours Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Female Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 028F 029F 030F Mean SD
Adipose tissue 0.110 0.274 0.162 0.182 0.084
Adrenal glands 1.429 8.981 2.285 4.232 4.135
Bladder 0.062 0.289 0.114 0.155 0.119
Bone (femur) 0.132 0.566 0.189 0.296 0.236
Bone marrow (femur) 0.575 1.722 1.714 1.337 0.660
Brain 0.063 0.241 0.095 0.133 0.095
Eyes 0.034 0.117 0.023 0.058 0.051
Heart 0.554 3.221 1.272 1.682 1.380
Injection site 0.092 1.744 277.600 93.144 159.740
Kidneys 0.623 2.870 5.408 2.967 2.394
Large intestine 0.027 0.198 0.092 0.106 0.086
Liver 5.209 21.794 10.108 12.370 8.521
Lung 0.908 4.000 1.313 2.074 1.681
Lymph node (Man) 0.198 0.701 0.188 0.362 0.293
Lymph node (Mes) 1.473 0.640 0.381 0.831 0.571
Muscle 0.045 0.140 0.114 0.100 0.049
Ovaries 0.474 2.683 1.756 1.638 1.109
Pancreas 0.116 0.825 0.270 0.404 0.373
Pituitary gland 0.414 1.853 0.599 0.955 0.783
Salivary glands 0.141 0.562 0.182 0.295 0.232
Skin 0.040 0.263 0.486 0.263 0.223
Small intestine 0.305 0.664 0.473 0.481 0.180
Spinal cord 0.109 0.289 0.118 0.172 0.102
Spleen 2.066 23.785 4.788 10.213 11.832
Stomach 0.088 0.211 0.077 0.126 0.074
Thymus 0.109 1.108 0.160 0.459 0.562
Thyroid 0.371 1.791 1.163 1.109 0.711
Uterus 0.169 0.568 0.178 0.305 0.228
Whole Blood 2.194 14.470 3.655 6.773 6.706
Plasma 4.442 15.480 7.350 9.091 5.721
Blood:plasma ratio 0.49 0.93 0.50 0.64 0.25
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014006
Page 46
Test Facility Study No: 185350
Appendix 5 Individual Female Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 4 h ours Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Female Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 031F 032F 033F Mean SD
Adipose tissue 0.134 0.061 0.296 0.163 0.121
Adrenal glands 1.879 3.483 4.255 3.206 1.212
Bladder 0.043 0.101 0.175 0.106 0.066
Bone (femur) 0.136 0.194 0.321 0.217 0.095
Bone marrow (femur) 0.448 0.818 1.480 0.915 0.522
Brain 0.033 0.058 0.133 0.075 0.052
Eyes 0.022 0.046 0.048 0.038 0.015
Heart 0.296 0.746 1.734 0.925 0.735
Injection site 8.920 103.630 56.133 56.227 47.355
Kidneys 0.328 0.627 1.486 0.814 0.601
Large intestine 0.165 0.222 0.283 0.224 0.059
Liver 8.503 14.685 20.519 14.569 6.009
Lung 0.610 1.159 1.898 1.222 0.646
Lymph node (Man) 0.173 0.454 0.546 0.391 0.194
Lymph node (Mes) 0.316 0.598 0.695 0.536 0.197
Muscle 0.033 0.057 0.301 0.130 0.148
Ovaries 0.555 2.916 3.552 2.341 1.579
Pancreas 0.358 0.270 0.568 0.398 0.153
Pituitary gland 0.251 0.317 0.805 0.458 0.303
Salivary glands 0.087 0.156 0.262 0.169 0.088
Skin 0.043 0.371 0.197 0.204 0.164
Small intestine 0.684 0.739 1.089 0.838 0.220
Spinal cord 0.073 0.061 0.236 0.124 0.098
Spleen 9.910 11.442 13.587 11.646 1.847
Stomach 0.050 0.113 0.141 0.101 0.047
Thymus 0.130 0.267 0.231 0.209 0.071
Thyroid 0.225 0.718 0.867 0.604 0.336
Uterus 0.080 0.096 0.246 0.140 0.091
Whole Blood 1.090 1.981 5.022 2.698 2.062
Plasma 2.037 3.442 7.274 4.251 2.711
Blood:plasma ratio 0.53 0.58 0.69 0.60 0.08
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014007
Page 47
Test Facility Study No: 185350
Appendix 5 Individual Female Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 8 h ours Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Female Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 034F 035F 036F Mean SD
Adipose tissue 0.095 0.041 0.072 0.069 0.027
Adrenal glands 7.562 6.554 7.538 7.218 0.575
Bladder 0.047 0.080 0.127 0.085 0.040
Bone (femur) 0.243 0.143 0.144 0.177 0.057
Bone marrow (femur) 1.262 1.350 1.210 1.274 0.071
Brain 0.047 0.030 0.058 0.045 0.014
Eyes 0.046 0.013 0.032 0.030 0.016
Heart 0.532 0.193 0.448 0.391 0.177
Injection site 30.227 174.950 172.620 125.930 82.890
Kidneys 0.416 0.239 0.372 0.342 0.092
Large intestine 0.679 0.381 0.764 0.608 0.201
Liver 22.242 25.442 27.834 25.172 2.806
Lung 0.661 0.378 0.846 0.628 0.236
Lymph node (Man) 0.315 0.251 0.551 0.372 0.158
Lymph node (Mes) 0.790 0.481 0.915 0.729 0.223
Muscle 0.040 0.160 0.075 0.091 0.062
Ovaries 2.960 1.276 5.029 3.088 1.880
Pancreas 0.390 0.087 0.241 0.239 0.151
Pituitary gland 0.169 0.099 0.157 0.141 0.037
Salivary glands 0.124 0.074 0.082 0.094 0.027
Skin 0.137 0.057 0.155 0.116 0.052
Small intestine 1.162 0.839 1.098 1.033 0.171
Spinal cord 0.051 0.021 0.060 0.044 0.020
Spleen 19.387 16.090 23.763 19.747 3.849
Stomach 0.243 0.040 0.094 0.126 0.105
Thymus 0.111 0.086 0.102 0.100 0.013
Thyroid 0.395 0.131 0.395 0.307 0.152
Uterus 0.584 0.055 0.223 0.287 0.270
Whole Blood 0.731 0.319 0.833 0.628 0.272
Plasma 1.421 0.574 1.447 1.147 0.496
Blood:plasma ratio 0.51 0.56 0.58 0.55 0.03
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014008
Page 48
Test Facility Study No: 185350
Appendix 5 Individual Female Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 24 h ours Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Female Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 037F 038F 039F Mean SD
Adipose tissue 0.031 0.042 0.053 0.042 0.011
Adrenal glands 9.718 3.981 9.084 7.595 3.145
Bladder 0.141 0.135 0.235 0.171 0.056
Bone (femur) 0.158 0.105 0.278 0.180 0.089
Bone marrow (femur) 1.180 1.058 1.978 1.405 0.500
Brain 0.040 0.039 0.063 0.047 0.014
Eyes 0.063 0.037 0.057 0.052 0.014
Heart 0.342 0.259 0.355 0.318 0.052
Injection site 2.568 202.540 162.510 122.540 105.810
Kidneys 0.270 0.412 0.361 0.348 0.072
Large intestine 0.561 0.370 0.465 0.466 0.095
Liver 13.368 10.520 21.469 15.119 5.681
Lung 0.519 0.822 0.945 0.762 0.219
Lymph node (Man) 0.259 0.242 0.589 0.363 0.195
Lymph node (Mes) 0.944 0.550 1.095 0.863 0.281
Muscle 0.028 0.114 0.133 0.092 0.056
Ovaries 4.091 5.266 6.363 5.240 1.136
Pancreas 0.176 0.362 0.422 0.320 0.128
Pituitary gland 0.309 0.213 0.379 0.300 0.083
Salivary glands 0.084 0.083 0.119 0.096 0.021
Skin 0.047 0.156 0.151 0.118 0.062
Small intestine 0.748 0.661 0.769 0.726 0.057
Spinal cord 0.047 0.034 0.064 0.048 0.015
Spleen 15.606 12.977 23.440 17.341 5.443
Stomach 0.094 0.054 0.096 0.081 0.024
Thymus 0.154 0.190 0.135 0.159 0.028
Thyroid 0.302 0.294 0.410 0.335 0.065
Uterus 0.307 0.207 0.354 0.289 0.075
Whole Blood 0.475 0.380 0.779 0.544 0.208
Plasma 0.930 0.681 1.223 0.945 0.271
Blood:plasma ratio 0.51 0.56 0.64 0.57 0.06
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014009
Page 49
Test Facility Study No: 185350
Appendix 5 Individual Female Concentration Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 48 h ours Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Female Wistar Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as µg lipid equiv /g (mL)
Sample 040F 041F 042F Mean SD
Adipose tissue 0.081 0.201 0.414 0.232 0.168
Adrenal glands 12.979 15.142 16.707 14.942 1.872
Bladder 0.234 0.640 0.293 0.389 0.219
Bone (femur) 0.299 1.911 0.351 0.854 0.916
Bone marrow (femur) 2.096 1.993 7.463 3.851 3.129
Brain 0.038 0.046 0.072 0.052 0.018
Eyes 0.064 0.105 0.121 0.097 0.029
Heart 0.352 0.369 0.539 0.420 0.103
Injection site 93.643 27.547 62.073 61.088 33.059
Kidneys 0.314 0.378 0.412 0.368 0.050
Large intestine 1.210 1.507 1.031 1.249 0.241
Liver 24.416 20.707 46.111 30.411 13.722
Lung 0.921 0.719 1.053 0.898 0.168
Lymph node (Man) 0.600 0.516 0.784 0.633 0.137
Lymph node (Mes) 1.557 1.669 1.800 1.675 0.122
Muscle 0.126 0.068 0.119 0.104 0.032
Ovaries 9.305 13.544 13.933 12.261 2.567
Pancreas 0.364 0.298 1.170 0.611 0.485
Pituitary gland 0.910 0.816 0.810 0.845 0.056
Salivary glands 0.200 0.204 0.288 0.231 0.049
Skin 0.303 0.173 0.416 0.297 0.122
Small intestine 1.142 1.461 1.339 1.314 0.161
Spinal cord 0.043 0.075 0.069 0.062 0.017
Spleen 19.456 16.775 45.234 27.155 15.714
Stomach 0.154 0.197 0.233 0.195 0.040
Thymus 0.314 0.248 0.536 0.366 0.151
Thyroid 0.584 0.870 0.512 0.655 0.190
Uterus 0.267 0.521 0.581 0.456 0.167
Whole Blood 0.258 0.338 0.320 0.305 0.042
Plasma 0.429 0.598 0.546 0.524 0.087
Blood:plasma ratio 0.60 0.57 0.59 0.58 0.02
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014010
Page 50
Test Facility Study No: 185350
Appendix 6 Individual Male Recovery Data
Recovery of Total Radioactivity in Tissues 0.25 min Following Single
Intramuscular Administration of [3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 043M 044M 045M Mean SD
Adrenal glands 0.002 0.002 0.000 0.001 0.001
Bladder 0.001 0.000 0.000 0.000 0.000
Brain 0.013 0.014 0.005 0.011 0.005
Eyes 0.001 0.000 0.000 0.000 0.000
Heart 0.056 0.024 0.004 0.028 0.026
Injection site 82.460 6.097 10.103 32.887 42.978
Kidneys 0.103 0.087 0.016 0.069 0.046
Large intestine 0.012 0.018 0.002 0.011 0.008
Liver 1.735 1.083 0.167 0.995 0.787
Lung 0.133 0.082 0.031 0.082 0.051
Pancreas 0.004 0.010 0.001 0.005 0.005
Pituitary gland 0.001 0.000 0.000 0.000 0.000
Prostate 0.002 0.002 0.000 0.001 0.001
Salivary glands 0.007 0.005 0.001 0.004 0.003
Small intestine 0.051 0.040 0.005 0.032 0.024
Spinal cord 0.002 0.001 0.000 0.001 0.001
Spleen 0.020 0.019 0.003 0.014 0.009
Stomach 0.008 0.013 0.002 0.008 0.006
Testes 0.012 0.008 0.001 0.007 0.005
Thymus 0.005 0.010 0.001 0.005 0.005
Thyroid 0.000 0.000 0.000 0.000 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014011
Page 51
Test Facility Study No: 185350
Appendix 6 Individual Male Re covery Data
(continued)
Recovery of Total Radioactivity in Tissues 1 h our Following Single
Intramuscular Administration of [3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % ad ministered dose
Sample 046M 047M 048M Mean SD
Adrenal glands 0.001 0.003 0.002 0.002 0.001
Bladder 0.001 0.001 0.000 0.001 0.000
Brain 0.005 0.014 0.013 0.010 0.005
Eyes 0.000 0.000 0.001 0.000 0.000
Heart 0.015 0.036 0.045 0.032 0.015
Injection sit e 74.148 46.614 85.725 68.829 20.090
Kidneys 0.047 0.086 0.098 0.077 0.027
Large intestine 0.016 0.017 0.021 0.018 0.002
Liver 2.218 2.607 3.676 2.834 0.755
Lung 0.043 0.131 0.081 0.085 0.044
Pancreas 0.004 0.009 0.006 0.006 0.003
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.001 0.002 0.001 0.001 0.001
Salivary glands 0.003 0.005 0.006 0.005 0.002
Small intestine 0.102 0.133 0.136 0.124 0.019
Spinal cord 0.001 0.000 0.001 0.001 0.000
Spleen 0.115 0.063 0.082 0.087 0.026
Stomach 0.007 0.019 0.023 0.016 0.008
Testes 0.007 0.009 0.013 0.010 0.003
Thymus 0.008 0.004 0.007 0.006 0.002
Thyroid 0.000 0.001 0.000 0.000 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014012
Page 52
Test Facility Study No: 185350
Appendix 6 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 2 h ours Followi ng Single
Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 049M 050M 051M Mean SD
Adrenal glands 0.006 0.003 0.005 0.005 0.001
Bladder 0.001 0.001 0.001 0.001 0.000
Brain 0.033 0.013 0.016 0.021 0.011
Eyes 0.001 0.000 0.002 0.001 0.001
Heart 0.109 0.036 0.051 0.065 0.039
Injection site 53.157 53.477 10.525 39.053 24.707
Kidneys 0.203 0.096 0.148 0.149 0.054
Large intestine 0.063 0.035 0.063 0.054 0.016
Liver 10.166 4.262 8.460 7.629 3.038
Lung 0.313 0.094 0.160 0.189 0.113
Pancreas 0.011 0.006 0.028 0.015 0.012
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.002 0.002 0.003 0.002 0.000
Salivary glan ds 0.010 0.004 0.008 0.007 0.003
Small intestine 0.418 0.305 0.336 0.353 0.058
Spinal cord 0.001 0.001 0.002 0.001 0.001
Spleen 0.296 0.101 0.299 0.232 0.114
Stomach 0.034 0.017 0.047 0.033 0.015
Testes 0.027 0.008 0.017 0.017 0.009
Thymus 0.010 0.005 0.008 0.008 0.002
Thyroid 0.001 0.001 0.000 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014013
Page 53
Test Facility Study No: 185350
Appendix 6 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 4 hours Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 052M 053M 054M Mean SD
Adrenal glands 0.013 0.009 0.014 0.012 0.002
Bladder 0.001 0.002 0.001 0.001 0.000
Brain 0.019 0.015 0.029 0.021 0.007
Eyes 0.002 0.002 0.001 0.002 0.001
Heart 0.071 0.033 0.096 0.067 0.032
Injection site 61.619 36.450 45.061 47.710 12.792
Kidneys 0.151 0.088 0.169 0.136 0.042
Large intestine 0.271 0.219 0.216 0.236 0.031
Liver 12.655 13.898 18.528 15.027 3.095
Lung 0.356 0.080 0.241 0.226 0.139
Pancreas 0.007 0.020 0.011 0.013 0.007
Pituitary gland 0.001 0.001 0.000 0.001 0.000
Prostate 0.003 0.002 0.003 0.003 0.001
Salivary glands 0.009 0.007 0.012 0.009 0.002
Small intestine 0.632 0.499 0.737 0.623 0.120
Spinal cord 0.002 0.004 0.002 0.003 0.001
Spleen 0.309 0.410 0.334 0.351 0.052
Stomach 0.053 0.027 0.033 0.037 0.013
Testes 0.028 0.021 0.039 0.030 0.009
Thymus 0.010 0.011 0.033 0.018 0.013
Thyroid 0.001 0.001 0.001 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014014
Page 54
Test Facility Study No: 185350
Appendix 6 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 8 hours Following Single
Intramuscular Administration of [3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results e xpressed as % administered dose
Sample 055M 056M 057M Mean SD
Adrenal glands 0.013 0.023 0.042 0.026 0.015
Bladder N.S. 0.001 0.002 0.002 N.A.
Brain 0.014 0.013 0.014 0.014 0.001
Eyes N.S. 0.001 0.002 0.002 N.A.
Heart 0.071 0.051 0.061 0.061 0.010
Injection site 18.863 19.984 17.346 18.731 1.324
Kidneys 0.114 0.107 0.108 0.109 0.004
Large intestine 0.536 0.424 0.430 0.463 0.063
Liver 17.280 17.862 29.414 21.519 6.844
Lung 0.226 0.146 0.169 0.180 0.042
Pancreas 0.010 0.021 0.012 0.014 0.006
Pituitary gland 0.000 0.000 0.001 0.000 0.000
Prostate 0.004 0.002 0.001 0.003 0.001
Salivary glands 0.008 0.006 0.007 0.007 0.001
Small intestine 0.850 1.034 1.031 0.972 0.106
Spinal cord 0.001 0.001 0.001 0.001 0.000
Spleen 1.037 1.022 1.293 1.118 0.152
Stomach 0.043 0.026 0.097 0.055 0.037
Testes 0.034 0.022 0.045 0.034 0.012
Thymus 0.013 0.010 0.012 0.012 0.001
Thyroid 0.001 0.001 0.001 0.001 0.000
N.S. = No sample due to oxidiser failure
N.A. = Not applicable
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014015
Page 55
Test Facility Study No: 185350
Appendix 6 Individual Male Reco very Data
(continued)
Recovery of Total Radioactivity in Tissues 24 h ours Following Single
Intramuscular Administration of [3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % ad ministered dose
Sample 058M 059M 060M Mean SD
Adrenal glands 0.052 0.059 0.137 0.083 0.047
Bladder 0.002 0.002 0.002 0.002 0.000
Brain 0.006 0.013 0.017 0.012 0.006
Eyes 0.002 0.002 0.004 0.002 0.001
Heart 0.051 0.026 0.026 0.035 0.014
Injection sit e 39.854 26.623 29.394 31.957 6.978
Kidneys 0.075 0.053 0.075 0.068 0.012
Large intestine 0.332 0.895 2.045 1.091 0.873
Liver 14.444 16.303 28.957 19.901 7.897
Lung 0.109 0.118 0.179 0.136 0.038
Pancreas 0.007 0.017 0.015 0.013 0.005
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.003 0.004 0.005 0.004 0.001
Salivary glands 0.005 0.008 0.012 0.008 0.004
Small intestine 0.693 1.198 1.934 1.275 0.624
Spinal cord 0.001 0.002 0.002 0.001 0.001
Spleen 0.977 0.660 1.234 0.957 0.287
Stomach 0.021 0.033 0.107 0.054 0.046
Testes 0.057 0.058 0.105 0.074 0.028
Thymus 0.007 0.010 0.009 0.009 0.002
Thyroid 0.001 0.001 0.001 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014016
Page 56
Test Facility Study No: 185350
Appendix 6 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 48 h ours Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 061M 062M 063M Mean SD
Adrenal glands 0.078 0.157 0.078 0.104 0.046
Bladder 0.001 0.002 0.002 0.002 0.000
Brain 0.006 0.016 0.012 0.011 0.005
Eyes 0.002 0.003 0.003 0.003 0.000
Heart 0.024 0.055 0.037 0.039 0.016
Injection site 49.053 18.355 31.059 32.823 15.425
Kidneys 0.045 0.104 0.063 0.071 0.031
Large intestine 0.541 0.624 1.264 0.810 0.395
Liver 12.962 17.164 11.734 13.953 2.848
Lung 0.088 0.173 0.133 0.131 0.043
Pancreas 0.010 0.013 0.023 0.015 0.007
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.002 0.004 0.004 0.003 0.001
Saliva ry glands 0.010 0.012 0.008 0.010 0.002
Small intestine 0.635 1.258 1.020 0.971 0.314
Spinal cord 0.001 0.001 0.002 0.001 0.001
Spleen 0.544 1.271 0.926 0.914 0.364
Stomach 0.027 0.065 0.056 0.049 0.019
Testes 0.053 0.109 0.060 0.074 0.030
Thymus 0.004 0.012 0.009 0.008 0.004
Thyroid 0.001 0.002 0.001 0.001 0.001
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014017
Page 57
Test Facility Study No: 185350
Appendix 7 Individual Female Recovery Data
Recovery of Total Radioactivity in Tissues 0.25 min Following Single
Intramuscular Administration of [3H]-08-A01-C01 to Female Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 022F 023F 024F Mean SD
Adrenal glands 0.003 *0.000 0.001 º0.001 º0.002
Bladder 0.000 *0.000 0.000 º0.000 º0.000
Brain 0.005 *0.000 0.002 º0.002 º0.002
Eyes 0.000 *0.000 0.000 º0.000 º0.000
Heart 0.017 *0.000 0.006 º0.008 º0.008
Injection site 8.145 11.578 0.723 6.815 5.549
Kidneys 0.063 0.012 0.014 0.030 0.028
Large intestine 0.010 *0.000 0.002 º0.004 º0.005
Liver 0.435 0.010 0.180 0.209 0.214
Lung 0.051 0.001 0.013 0.022 0.026
Ovaries 0.002 *0.000 0.001 º0.001 º0.001
Pancreas 0.002 0.000 0.001 0.001 0.001
Pituitary gland 0.000 *0.000 0.000 º0.000 º0.000
Salivary glands 0.004 *0.000 0.001 º0.002 º0.002
Small intestine 0.038 *0.001 0.005 º0.015 º0.020
Spinal cord 0.000 *0.000 0.000 º0.000 º0.000
Spleen 0.014 *0.000 0.017 º0.011 º0.009
Stomach 0.007 *0.000 0.002 º0.003 º0.003
Thymus 0.005 *0.000 0.002 º0.002 º0.002
Thyroid 0.000 *0.000 0.000 º0.000 º0.000
Uterus 0.004 *0.000 0.002 º0.002 º0.002
*=Results calculated from data less than 30 cpm above background
°=Mean includes results calculated from data less than 30 cpm above background
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014018
Page 58
Test Facility Study No: 185350
Appendix 7 Individual Female Recovery Data
(continued)
Recovery of Total Radioactivity in Tissu es 1 h our Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to Female Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 025F 026F 027F Mean SD
Adrenal glands 0.010 0.011 0.015 0.012 0.003
Bladder 0.001 0.001 0.001 0.001 0.000
Brain 0.013 0.019 0.015 0.016 0.003
Eyes 0.001 0.001 0.001 0.001 0.000
Heart 0.066 0.109 0.062 0.079 0.026
Injection site 10.609 47.776 50.847 36.411 22.398
Kidneys 0.162 0.250 0.102 0.171 0.074
Large intestine 0.030 0.035 0.029 0.032 0.003
Liver 3.586 2.713 2.421 2.907 0.606
Lung 0.112 0.131 0.106 0.117 0.013
Ovaries 0.012 0.010 0.004 0.009 0.004
Pancreas 0.009 0.009 0.007 0.008 0.001
Pituitary gland 0.000 0.001 0.001 0.001 0.000
Salivary glands 0.008 0.009 0.006 0.008 0.002
Small intestine 0.153 0.130 0.121 0.135 0.017
Spinal cord 0.002 0.002 0.001 0.002 0.001
Spleen 0.082 0.099 0.112 0.098 0.015
Stomach 0.024 0.021 0.023 0.022 0.002
Thymus 0.007 0.013 0.004 0.008 0.005
Thyroid 0.001 0.001 0.001 0.001 0.000
Uterus 0.008 0.010 0.015 0.011 0.004
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014019
Page 59
Test Facility Study No: 185350
Appendix 7 Individual Female Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 2 h ours Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to F emale Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 028F 029F 030F Mean SD
Adrenal glands 0.010 0.022 0.012 0.015 0.006
Bladder 0.000 0.001 0.001 0.001 0.001
Brain 0.008 0.034 0.014 0.019 0.014
Eyes 0.001 0.003 0.000 0.001 0.001
Heart 0.028 0.201 0.077 0.102 0.089
Injection site 0.018 0.236 72.027 24.094 41.511
Kidneys 0.056 0.264 0.497 0.272 0.221
Large intestine 0.018 0.142 0.065 0.075 0.063
Liver 3.203 12.436 5.452 7.030 4.815
Lung 0.080 0.311 0.110 0.167 0.125
Ovaries 0.003 0.012 0.009 0.008 0.004
Pancreas 0.003 0.022 0.010 0.012 0.010
Pituitary gland 0.000 0.002 0.000 0.001 0.001
Salivary glands 0.005 0.015 0.007 0.009 0.006
Small intestine 0.205 0.367 0.283 0.285 0.081
Spinal cord 0.002 0.004 0.001 0.002 0.002
Spleen 0.063 1.010 0.180 0.418 0.516
Stomach 0.027 0.057 0.022 0.035 0.019
Thymus 0.003 0.028 0.004 0.012 0.014
Thyroid 0.000 0.002 0.001 0.001 0.001
Uterus 0.008 0.025 0.011 0.015 0.009
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014020
Page 60
Test Facility Study No: 185350
Appendix 7 Individual Female Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 4 hours Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to Female Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid /Animal
Results expressed as % administered dose
Sample 031F 032F 033F Mean SD
Adrenal glands 0.011 0.019 0.023 0.018 0.006
Bladder 0.000 0.001 0.001 0.001 0.000
Brain 0.005 0.007 0.020 0.011 0.008
Eyes 0.001 0.001 0.001 0.001 0.000
Heart 0.013 0.046 0.097 0.052 0.042
Injection site 2.619 19.042 5.508 9.056 8.768
Kidneys 0.031 0.062 0.154 0.082 0.064
Large intestine 0.111 0.136 0.198 0.148 0.045
Liver 5.207 8.846 12.045 8.699 3.421
Lung 0.054 0.093 0.188 0.112 0.069
Ovaries 0.003 0.022 0.022 0.016 0.011
Pancreas 0.016 0.009 0.027 0.017 0.009
Pituitary gland 0.000 0.000 0.001 0.000 0.000
Salivary glands 0.003 0.005 0.011 0.006 0.005
Small intestine 0.354 0.435 0.596 0.462 0.123
Spinal cord 0.001 0.001 0.003 0.002 0.001
Spleen 0.390 0.421 0.447 0.419 0.028
Stomach 0.014 0.022 0.029 0.022 0.008
Thymus 0.004 0.007 0.006 0.006 0.002
Thyroid 0.000 0.001 0.001 0.001 0.000
Uterus 0.005 0.004 0.016 0.008 0.007
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014021
Page 61
Test Facility Study No: 185350
Appendix 7 Individual Female Recovery Data
(continued)
Recovery of Total Radioac tivity in Tissues 8 hours Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to Female Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 034F 035F 036F Mean SD
Adrenal glands 0.048 0.031 0.051 0.043 0.011
Bladder 0.000 0.000 0.001 0.000 0.000
Brain 0.007 0.004 0.009 0.007 0.002
Eyes 0.001 0.000 0.001 0.001 0.000
Heart 0.029 0.010 0.027 0.022 0.011
Injection site 10.296 26.182 38.500 24.993 14.139
Kidneys 0.056 0.022 0.042 0.040 0.017
Large intestine 0.409 0.233 0.397 0.346 0.098
Liver 13.264 12.033 18.443 14.580 3.402
Lung 0.089 0.028 0.074 0.064 0.031
Ovaries 0.022 0.010 0.042 0.025 0.016
Pancreas 0.034 0.002 0.011 0.016 0.016
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Salivary glands 0.005 0.002 0.003 0.003 0.001
Small intestine 0.718 0.308 0.714 0.580 0.235
Spinal cord 0.001 0.000 0.001 0.001 0.000
Spleen 0.853 0.601 1.082 0.845 0.241
Stomach 0.043 0.005 0.023 0.024 0.019
Thymus 0.004 0.002 0.003 0.003 0.001
Thyroid 0.001 0.000 0.001 0.000 0.000
Uterus 0.030 0.004 0.014 0.016 0.013
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014022
Page 62
Test Facility Study No: 185350
Appendix 7 Individual Female Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 24 hours Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to Female Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Animal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 037F 038F 039F Mean SD
Adrenal glands 0.064 0.032 0.050 0.049 0.016
Bladder 0.001 0.001 0.001 0.001 0.000
Brain 0.005 0.006 0.009 0.007 0.002
Eyes 0.001 0.001 0.001 0.001 0.000
Heart 0.019 0.014 0.020 0.018 0.003
Injection site 0.444 39.677 38.765 26.295 22.392
Kidneys 0.029 0.053 0.035 0.039 0.013
Large intestine 0.334 0.283 0.263 0.293 0.037
Liver 9.112 9.776 14.042 10.977 2.675
Lung 0.053 0.071 0.072 0.065 0.010
Ovaries 0.031 0.038 0.043 0.037 0.006
Pancreas 0.005 0.007 0.014 0.009 0.004
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Salivary glands 0.003 0.003 0.004 0.003 0.001
Small intestine 0.575 0.601 0.432 0.536 0.091
Spinal cord 0.001 0.001 0.001 0.001 0.000
Spleen 0.591 0.508 0.955 0.685 0.237
Stomach 0.019 0.011 0.029 0.020 0.009
Thymus 0.003 0.005 0.003 0.004 0.001
Thyroid 0.000 0.000 0.001 0.000 0.000
Uterus 0.027 0.009 0.017 0.018 0.009
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014023
Page 63
Test Facility Study No: 185350
Appendix 7 Individual Female Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 48 h ours Following Single
Intramuscular Administration of [
3H]-08-A01-C01 to Female Wistar
Han Rats
Target Dose Level: 50 µg mRNA/Ani mal; 1.29 mg Total Lipid/Animal
Results expressed as % administered dose
Sample 040F 041F 042F Mean SD
Adrenal glands 0.085 0.126 0.114 0.108 0.021
Bladder 0.001 0.004 0.002 0.002 0.001
Brain 0.005 0.006 0.010 0.007 0.002
Eyes 0.001 0.003 0.003 0.002 0.001
Heart 0.018 0.017 0.024 0.020 0.004
Injection site 20.139 5.852 23.287 16.426 9.292
Kidneys 0.036 0.045 0.044 0.042 0.005
Large intestine 0.570 0.928 0.644 0.714 0.189
Liver 15.122 13.811 26.137 18.357 6.770
Lung 0.066 0.066 0.076 0.070 0.006
Ovaries 0.075 0.113 0.097 0.095 0.019
Pancreas 0.011 0.007 0.050 0.023 0.024
Pituitary gland 0.001 0.001 0.000 0.001 0.000
Salivary glands 0.007 0.005 0.009 0.007 0.002
Small intestine 0.540 0.825 0.729 0.698 0.145
Spinal cord 0.001 0.002 0.001 0.001 0.000
Spleen 0.772 0.848 1.818 1.146 0.583
Stomach 0.023 0.028 0.035 0.029 0.006
Thymus 0.007 0.005 0.009 0.007 0.002
Thyroid 0.001 0.001 0.001 0.001 0.000
Uterus 0.010 0.031 0.025 0.022 0.010
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014024
Page 64
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA data
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 0.25 min Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as µg lipid equiv/g (mL)
Sample 001M 002M 003M Mean SD
Adipose tissue 0.075 0.108 0.018 0.067 0.046
Adrenal glands 0.193 0.192 0.184 0.190 0.005
Bladder 0.035 0.079 0.026 0.047 0.028
Bone (femur) 0.195 0.054 0.044 0.098 0.085
Bone marrow (femur) 0.312 0.163 0.229 0.234 0.075
Brain 0.050 0.047 0.046 0.048 0.002
Eyes 0.015 0.021 0.007 0.014 0.007
Heart 0.394 0.365 0.460 0.406 0.048
Injection site 16.832 24.313 179.840 73.662 92.030
Kidneys 0.576 0.552 0.273 0.467 0.169
Large intestine 0.016 0.012 0.051 0.026 0.022
Liver 0.963 0.503 0.670 0.712 0.233
Lung 0.689 0.497 0.410 0.532 0.143
Lymph node (Man) 0.043 0.046 0.042 0.044 0.002
Lymph node (Mes) 0.045 0.020 0.018 0.028 0.015
Muscle 0.035 0.040 0.285 0.120 0.143
Pancreas 0.088 0.068 0.068 0.075 0.012
Pituitary gland 0.787 0.796 0.225 0.603 0.327
Prostate 0.035 0.045 0.047 0.042 0.006
Salivary glands 0.087 0.087 0.049 0.074 0.022
Skin 2.094 3.233 12.691 6.499 6.668
Small intestine 0.046 0.030 0.016 0.031 0.015
Spinal cord 0.091 0.064 0.068 0.074 0.015
Spleen 0.426 1.463 0.221 0.704 0.666
Stomach 0.032 0.026 *0.007 º0.022 º0.013
Testes 0.033 0.030 0.020 0.028 0.007
Thymus 0.121 0.161 0.216 0.166 0.048
Thyroid 0.175 0.498 0.105 0.259 0.209
Whole Blood 2.291 2.426 1.678 2.132 0.398
Plasma 5.640 5.530 3.924 5.031 0.960
Blood:plasma ratio 0.41 0.44 0.43 0.42 0.02
*=Results calculated from data less than 30 cpm above background
°=Mean includes results calculated from data less than 30 cpm above background
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014025
Page 65
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 1 hour Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Result s expressed as µg lipid equiv/g (mL)
Sample 004M 005M 006M Mean SD
Adipose tissue 0.193 0.307 0.350 0.283 0.081
Adrenal glands 1.775 1.877 2.208 1.953 0.227
Bladder 0.224 0.098 0.264 0.195 0.086
Bone (femur) 1.102 0.530 0.566 0.733 0.320
Bone marrow (femur) 2.111 4.732 2.456 3.100 1.424
Brain 0.253 0.297 0.296 0.282 0.025
Eyes 0.229 0.070 0.093 0.131 0.086
Heart 1.948 3.461 2.496 2.635 0.766
Injection site 152.370 78.654 150.890 127.300 42.139
Kidneys 3.017 3.096 3.170 3.094 0.077
Large intestin e 0.090 0.091 0.152 0.111 0.035
Liver 13.805 10.906 16.323 13.678 2.711
Lung 3.523 3.532 2.901 3.319 0.362
Lymph node (Man) 0.366 0.379 0.437 0.394 0.038
Lymph node (Mes) 0.268 0.412 0.389 0.356 0.077
Muscle 0.184 0.213 0.195 0.198 0.015
Pancreas 0.335 0.375 0.469 0.393 0.069
Pituitary gland 1.389 1.810 1.717 1.639 0.221
Prostate 0.328 0.363 0.380 0.357 0.027
Salivary glands 0.471 0.613 0.493 0.526 0.076
Skin 3.043 0.407 1.179 1.543 1.355
Small intestine 0.393 3.191 3.563 2.382 1.733
Spinal cord 0.216 0.356 0.303 0.292 0.071
Spleen 4.066 4.402 4.868 4.445 0.402
Stomach 0.332 2.377 8.099 3.603 4.026
Testes 0.185 0.196 0.486 0.289 0.171
Thymus 0.332 0.343 0.596 0.424 0.149
Thyroid 1.219 1.909 1.266 1.465 0.385
Whole Blood 7.985 11.835 10.357 10.059 1.942
Plasma 23.703 26.782 26.070 25.518 1.612
Blood:plasma ratio 0.34 0.44 0.40 0.39 0.05
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014026
Page 66
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 2 hours Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as µg lipid equiv/g (mL)
Sample 007M 008M 009M Mean SD
Adipose tissue 0.311 0.211 0.486 0.336 0.140
Adrenal glands 3.152 3.337 2.559 3.016 0.406
Bladder 0.310 0.241 0.479 0.343 0.122
Bone (femur) 0.835 0.462 0.385 0.561 0.241
Bone marrow (femur) 3.322 2.694 2.057 2.691 0.632
Brain 0.348 0.310 0.250 0.302 0.049
Eyes 0.126 0.104 0.064 0.098 0.031
Heart 2.866 3.359 3.481 3.235 0.326
Injection site 6.971 61.485 30.751 33.069 27.331
Kidneys 2.887 2.858 2.679 2.808 0.113
Large intestine 0.283 0.125 0.148 0.185 0.085
Liver 33.320 24.542 22.034 26.632 5.926
Lung 3.839 2.982 3.769 3.530 0.476
Lym ph node (Man) 0.784 0.413 0.474 0.557 0.199
Lymph node (Mes) 0.859 0.503 0.333 0.565 0.268
Muscle 0.220 0.182 0.189 0.197 0.020
Pancreas 0.595 0.512 0.557 0.554 0.041
Pituitary gland 1.998 1.921 1.729 1.883 0.139
Prostate 0.458 0.354 0.461 0.424 0.061
Salivary glands 0.740 0.597 0.539 0.625 0.104
Skin 0.524 0.353 0.454 0.444 0.086
Small intestine 1.147 0.887 0.755 0.930 0.199
Spinal cord 0.396 0.373 0.360 0.377 0.018
Spleen 14.103 8.227 7.803 10.044 3.521
Stomach 0.234 0.142 0.143 0.173 0.053
Testes 0.239 0.402 0.317 0.320 0.081
Thymus 0.447 0.424 0.371 0.414 0.039
Thyroid 1.906 1.397 1.481 1.595 0.273
Whole Blood 11.413 10.005 10.736 10.718 0.704
Plasma 25.479 22.927 22.340 23.582 1.669
Blood:plasma ratio 0.45 0.44 0.48 0.45 0.02
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014027
Page 67
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and Tissues 4 hours Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 100 µg mRNA/Ani mal; 2.57 mg Total Lipid/Animal
Results expressed as µg lipid equiv/g (mL)
Sample 010M 011M 012M Mean SD
Adipose tissue 0.222 0.262 0.105 0.196 0.082
Adrenal glands 5.481 2.469 2.491 3.480 1.732
Bladder 0.237 0.151 0.156 0.181 0.048
Bone (femur) 1.452 1.249 0.348 1.016 0.588
Bone marrow (femur) 1.880 3.875 1.459 2.405 1.291
Brain 0.373 0.123 0.090 0.195 0.155
Eyes 0.095 0.056 0.042 0.065 0.027
Heart 1.233 1.095 1.064 1.131 0.090
Injection site 55.286 464.630 257.860 259.260 204.680
Kidneys 2.190 1.607 1.007 1.601 0.591
Large intestine 0.180 0.713 0.338 0.410 0.274
Liver 38.606 14.955 19.426 24.329 12.565
Lung 1.255 3.060 1.398 1.904 1.003
Lymph node (Man) 0.694 0.271 0.242 0.402 0.253
Lymph node (Mes) 0.970 0.427 0.502 0.633 0.294
Muscle 0.129 0.076 0.085 0.097 0.029
Pancreas 0.189 0.419 0.299 0.302 0.115
Pituitary gland 0.870 0.599 0.480 0.649 0.200
Prostate 0.244 0.133 0.133 0.170 0.064
Salivary glands 0.334 0.192 0.170 0.232 0.089
Skin 0.931 0.178 2.172 1.094 1.007
Small intestine 0.758 1.381 1.189 1.110 0.319
Spinal cord 0.154 0.094 0.111 0.120 0.031
Spleen 9.286 27.731 9.780 15.599 10.510
Stomach 0.057 0.131 0.302 0.163 0.125
Testes 0.397 0.134 0.110 0.214 0.159
Thymus 0.164 0.229 0.185 0.193 0.033
Thyroid 1.256 0.565 0.742 0.854 0.359
Whole Blood 4.741 2.416 2.502 3.220 1.318
Plasma 11.200 5.253 5.862 7.438 3.272
Blood:plasma ratio 0.42 0.46 0.43 0.44 0.02
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014028
Page 68
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 8 hours Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as µg lipid equiv/g (mL)
Sample 013M 014M 015M Mean SD
Adipose tissue 0.134 0.147 0.269 0.184 0.075
Adrenal glands 6.445 9.564 32.615 16.208 14.294
Bladder 0.741 0.264 0.499 0.501 0.238
Bone (femur) 0.835 0.274 0.855 0.655 0.330
Bone marrow (femur) 1.920 1.495 2.225 1.880 0.367
Brain 0.165 0.120 0.214 0.166 0.047
Eyes 0.188 0.146 0.229 0.188 0.041
Heart 2.084 1.104 2.398 1.862 0.675
Injection site 126.340 106.800 2.416 78.521 66.629
Kidneys 2.145 1.122 1.472 1.580 0.520
Large intestine 1.713 1.199 1.781 1.564 0.318
Liver 34.463 41.789 61.002 45.751 13.706
Lung 2.999 1.707 3.360 2.689 0.869
Lymph node (Man) 1.158 0.644 1.099 0.967 0.282
Lymph node (Mes) 1.076 1.409 1.701 1.395 0.313
Muscle 0.158 0.096 0.196 0.150 0.051
Pancreas 0.433 0.326 0.579 0.446 0.127
Pituitary gland 0.858 0.517 0.994 0.790 0.246
Prostate 0.314 0.176 0.386 0.292 0.107
Salivary glands 0.242 0.168 0.386 0.265 0.111
Skin 0.295 0.285 0.547 0.376 0.148
Small intestine 2.012 1.963 1.865 1.946 0.075
Spinal cord 0.185 0.148 0.252 0.195 0.053
Spleen 24.956 16.693 35.344 25.664 9.345
Stomach 0.113 0.187 2.187 0.829 1.177
Testes 0.269 0.328 0.361 0.319 0.047
Thymus 0.110 0.295 0.481 0.295 0.185
Thyroid 1.544 0.885 2.170 1.533 0.642
Whole Blood 3.450 2.106 4.202 3.253 1.062
Plasma 7.541 4.597 8.168 6.768 1.907
Blood:plasma rati o 0.46 0.46 0.51 0.48 0.03
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014029
Page 69
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(continued)
Concentration of Total Radioactivity in Whole Blood, Plasma and
Tissues 24 hours Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as µg lipid equiv/g (mL)
Sample 016M 017M 018M Mean SD
Adipose tissue 0.268 0.219 0.261 0.249 0.027
Adrenal glands 63.795 42.538 52.924 53.085 10.629
Bladder 0.609 0.643 0.373 0.542 0.147
Bone (femur) 1.254 2.075 0.950 1.426 0.582
Bone marrow (femur) 5.002 4.711 7.513 5.742 1.541
Brain 0.186 0.221 0.255 0.221 0.034
Eyes 0.342 0.247 0.360 0.316 0.061
Heart 1.613 1.877 1.760 1.750 0.132
Injection site 50.606 70.405 268.240 129.750 120.340
Kidneys 1.971 1.774 2.460 2.068 0.353
Large intestine 5.083 2.282 3.210 3.525 1.427
Liver 51.485 71.224 45.827 56.179 13.334
Lung 3.831 3.615 3.360 3.602 0.236
Lymph node (Man) 3.227 1.555 1.570 2.117 0.961
Lymph node (Mes ) 5.835 3.496 3.765 4.366 1.279
Muscle 0.208 0.263 0.247 0.239 0.028
Pancreas 0.767 0.966 0.781 0.838 0.111
Pituitary gland 1.320 1.362 1.603 1.428 0.152
Prostate 0.407 0.446 0.481 0.445 0.037
Salivary glands 0.617 0.561 0.701 0.626 0.071
Skin 0.833 0.937 0.645 0.805 0.148
Small intestine 3.736 3.157 3.433 3.442 0.289
Spinal cord 0.229 0.200 0.326 0.252 0.066
Spleen 47.746 74.940 44.431 55.706 16.739
Stomach 0.572 0.802 0.489 0.621 0.162
Testes 0.638 0.502 0.616 0.585 0.073
Thymus 0.473 0.568 0.506 0.516 0.048
Thyroid 1.845 1.890 2.651 2.129 0.453
Whole Blood 2.448 1.756 3.404 2.536 0.827
Plasma 5.639 5.297 8.191 6.376 1.581
Blood:plasma ratio 0.43 0.33 0.42 0.39 0.05
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014030
Page 70
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(continued)
Concentration o f Total Radioactivity in Whole Blood, Plasma and
Tissues 48 hours Following Single Intramuscular Administration of
[3H]-08-A01-C01 to Male Wistar Han Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as µg lipid equ iv/g (mL)
Sample 019M 020M Mean
Adipose tissue 0.276 0.234 0.255
Adrenal glands 52.496 45.684 49.090
Bladder 0.779 0.849 0.814
Bone (femur) 0.639 0.867 0.753
Bone marrow (femur) 3.233 2.890 3.062
Brain 0.477 0.173 0.325
Eyes 0.239 0.260 0.249
Hear t 1.132 1.158 1.145
Injection site 48.800 59.876 54.338
Kidneys 0.971 1.131 1.051
Large intestine 4.144 2.190 3.167
Liver 48.512 36.690 42.601
Lung 1.853 2.477 2.165
Lymph node (Man) 2.418 1.157 1.788
Lymph node (Mes) 5.067 3.297 4.182
Muscle 0.166 0.926 0.546
Pancreas 0.540 0.701 0.620
Pituitary gland 0.987 0.884 0.936
Prostate 0.308 0.285 0.296
Salivary glands 0.488 0.588 0.538
Skin 0.640 0.699 0.670
Small intestine 3.644 3.750 3.697
Spinal cord 0.212 0.237 0.224
Spleen 35.545 33.899 34.72 2
Stomach 0.794 1.011 0.903
Testes 0.523 0.555 0.539
Thymus 0.514 0.655 0.584
Thyroid 1.604 1.523 1.564
Whole Blood 0.967 1.011 0.989
Plasma 1.451 1.493 1.472
Blood:plasma ratio 0.67 0.68 0.67
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014031
Page 71
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(conti nued)
Recovery of Total Radioactivity in Tissues 0.25 min Following Single
Intramuscular Administration of [3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as % administered dose
Sample 001M 002M 003M Mean SD
Adrenal glands 0.000 0.000 0.000 0.000 0.000
Bladder 0.000 0.000 0.000 0.000 0.000
Brain 0.003 0.003 0.003 0.003 0.000
Eyes 0.000 0.000 0.000 0.000 0.000
Heart 0.011 0.009 0.017 0.013 0.004
Injection site 1.865 3.345 18.252 7.821 9.064
Kidneys 0.037 0.033 0.019 0.030 0.010
Large intestine 0.006 0.004 0.018 0.009 0.008
Liver 0.368 0.185 0.278 0.277 0.091
Lung 0.028 0.017 0.023 0.023 0.005
Pancreas 0.001 0.001 0.002 0.001 0.000
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.000 0.000 0.000 0.000 0.000
Salivary glands 0.001 0.002 0.001 0.001 0.000
Small intestine 0.016 0.009 0.006 0.010 0.005
Spinal cord 0.001 0.001 0.000 0.001 0.000
Spleen 0.010 0.026 0.006 0.014 0.011
Stomach 0.005 0.004 *0.002 º0.003 º0.002
Testes 0.004 0.003 0.003 0.003 0.001
Thymus 0.003 0.003 0.004 0.003 0.001
Thyroid 0.000 0.000 0.000 0.000 0.000
*=Results calculated from data less than 30 cpm above background
°=Mean includes results calculated from data less than 30 cpm abo ve background
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014032
Page 72
Test Facility Study No: 185350
Appendix 8 Individual Male 100 µg mRNA Data
(continued)
Recovery of Total Radioactivity in Tissues 1 hour Following Single
Intramuscular Administration of [3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as % administered dose
Sample 004M 005M 006M Mean SD
Adrenal glands 0.005 0.003 0.004 0.004 0.001
Bladder 0.001 0.000 0.001 0.001 0.000
Brain 0.019 0.020 0.020 0.019 0.001
Eyes 0.002 0.001 0.001 0.001 0.001
Heart 0.049 0.103 0.074 0.075 0.027
Injection site 15.619 13.609 16.094 15.107 1.319
Kidneys 0.191 0.176 0.188 0.185 0.008
Large intestine 0.024 0.027 0.050 0.034 0.014
Liver 5.198 3.856 5.564 4.873 0.899
Lung 0.148 0.159 0.103 0.137 0.030
Pancreas 0.004 0.006 0.007 0.006 0.002
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.003 0.003 0.003 0.003 0.000
Salivary glands 0.007 0.009 0.011 0.009 0.002
Small intestine 0.132 1.003 1.062 0.732 0.521
Spinal cord 0.001 0.003 0.001 0.002 0.001
Spleen 0.090 0.087 0.089 0.089 0.001
Stomach 0.075 0.362 1.259 0.565 0.618
Testes 0.020 0.021 0.057 0.033 0.021
Thymus 0.007 0.005 0.006 0.006 0.001
Thyroid 0.001 0.001 0.001 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014033
Page 73
Test Facility Study No: 185350
Appendix 8 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 2 hours Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as % administered dose
Sample 007M 008M 009M Mean SD
Adrenal glands 0.008 0.006 0.007 0.007 0.001
Bladder 0.001 0.001 0.001 0.001 0.000
Brain 0.024 0.021 0.018 0.021 0.003
Eyes 0.001 0.001 0.001 0.001 0.000
Heart 0.078 0.095 0.115 0.096 0.019
Injection site 0.598 9.070 3.532 4.400 4.302
Kidneys 0.180 0.148 0.160 0.163 0.016
Large intestine 0.088 0.038 0.055 0.061 0.025
Liver 11.802 8.114 8.654 9.523 1.992
Lung 0.147 0.112 0.153 0.137 0.022
Pancreas 0.008 0.007 0.011 0.009 0.002
Pituitary gland 0.001 0.000 0.000 0.000 0.000
Prostate 0.003 0.004 0.004 0.004 0.001
Salivary glands 0.012 0.010 0.013 0.011 0.002
Small intestine 0.434 0.294 0.281 0.336 0.085
Spinal cord 0.003 0.004 0.002 0.003 0.001
Spleen 0.271 0.155 0.192 0.206 0.059
Stomach 0.036 0.023 0.026 0.028 0.007
Testes 0.025 0.045 0.036 0.035 0.010
Thymus 0.010 0.008 0.007 0.008 0.001
Thyroid 0.001 0.001 0.001 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014034
Page 74
Test Facility Study No: 185350
Appendix 8 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 4 hours Following Single Intramuscular Administrat ion of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as % administered dose
Sample 010M 011M 012M Mean SD
Adrenal glands 0.010 0.005 0.005 0.007 0.003
Bladder 0.001 0.000 0.000 0.001 0.000
Brain 0.027 0.009 0.006 0.014 0.011
Eyes 0.001 0.001 0.000 0.001 0.000
Heart 0.031 0.043 0.033 0.036 0.007
Injection site 5.231 59.191 24.168 29.530 27.377
Kidneys 0.141 0.101 0.058 0.100 0.041
Large intestine 0.062 0.258 0.123 0.147 0.100
Liver 13.675 6.428 7.436 9.180 3.926
Lung 0.079 0.141 0.069 0.096 0.039
Pancreas 0.003 0.008 0.006 0.006 0.003
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.002 0.001 0.001 0.001 0.001
Salivary glands 0.005 0.003 0.003 0.004 0.001
Small intestine 0.234 0.614 0.356 0.401 0.194
Spinal cord 0.001 0.001 0.001 0.001 0.000
Spleen 0.177 0.530 0.167 0.291 0.207
Stomach 0.007 0.035 0.043 0.028 0.019
Testes 0.048 0.017 0.012 0.026 0.019
Thymus 0.003 0.005 0.003 0.003 0.001
Thyroid 0.001 0.000 0.001 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014035
Page 75
Test Facility Study No: 185350
Appendix 8 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 8 hours Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as % administered dose
Sample 013M 014M 015M Mean SD
Adrenal glands 0.025 0.021 0.080 0.042 0.033
Bladder 0.002 0.001 0.001 0.001 0.001
Brain 0.012 0.009 0.014 0.012 0.003
Eyes 0.002 0.001 0.002 0.002 0.001
Heart 0.058 0.035 0.081 0.058 0.023
Injection site 8.806 17.803 0.313 8.974 8.746
Kidneys 0.134 0.073 0.091 0.099 0.031
Large intestine 0.511 0.398 0.634 0.514 0.118
Liver 11.864 16.293 24.504 17.553 6.414
Lung 0.192 0.129 0.197 0.172 0.038
Pancreas 0.005 0.006 0.012 0.007 0.004
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.002 0.001 0.003 0.002 0.001
Salivary glands 0.004 0.003 0.008 0.005 0.003
Small intestine 0.585 0.529 0.633 0.582 0.052
Spinal cord 0.002 0.001 0.002 0.002 0.000
Spleen 0.560 0.369 0.848 0.592 0.241
Stomach 0.021 0.019 0.288 0.109 0.155
Testes 0.031 0.036 0.038 0.035 0.004
Thymus 0.002 0.004 0.007 0.004 0.002
Thyroid 0.001 0.001 0.001 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014036
Page 76
Test Facility Study No: 185350
Appendix 8 Individual Male Recovery Data
(continu ed)
Recovery of Total Radioactivity in Tissues 24 hours Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as % administered dose
Sample 016M 017M 018M Mean SD
Adrenal glands 0.137 0.095 0.106 0.113 0.022
Bladder 0.003 0.002 0.001 0.002 0.001
Brain 0.012 0.015 0.019 0.015 0.003
Eyes 0.004 0.002 0.004 0.003 0.001
Heart 0.038 0.052 0.051 0.047 0.008
Injection site 3.590 15.406 29.435 16.144 12.938
Kidneys 0.107 0.104 0.165 0.125 0.034
Large intestine 1.668 0.752 0.996 1.139 0.475
Liver 22.736 26.544 20.865 23.382 2.894
Lung 0.170 0.160 0.226 0.185 0.036
Pancreas 0.010 0.016 0.012 0.013 0.003
Pituitary gland 0.000 0.000 0.000 0.000 0.000
Prostate 0.003 0.004 0.004 0.004 0.000
Salivary glands 0.011 0.010 0.011 0.010 0.001
Small intestine 1.194 0.896 1.321 1.137 0.218
Spinal cord 0.002 0.001 0.002 0.002 0.001
Spleen 1.003 1.590 1.111 1.234 0.312
Stomach 0.066 0.099 0.065 0.077 0.019
Testes 0.070 0.056 0.075 0.067 0.010
Thymus 0.007 0.009 0.007 0.008 0.002
Thyroid 0.001 0.001 0.001 0.001 0.000
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014037
Page 77
Test Facility Study No: 185350
Appendix 8 Individual Male Recovery Data
(continued)
Recovery of Total Radioactivity in Tissues 48 hours Following Single Intramuscular Administration of [
3H]-08-A01-C01 to Male Wistar Han
Rats
Target Dose Level: 100 µg mRNA/Animal; 2.57 mg Total Lipid/Animal Results expressed as % administered dose
Sample 019M 020M Mean
Adrenal glands 0.155 0.112 0.134
Bladder 0.002 0.002 0.002
Brain 0.034 0.012 0.023
Eyes 0.002 0.003 0.002
Heart 0.030 0.031 0.030
Injection site 2.978 10.414 6.696
Kidneys 0.063 0.076 0.070
Large intestine 1.070 0.719 0.894
Liver 17.436 16.159 16.797
Lung 0.071 0.132 0.102
Pancreas 0.007 0.006 0.006
Pituitary gland 0.000 0.000 0.000
Prostate 0.003 0.002 0.003
Salivary glands 0.008 0.009 0.008
Small intestine 0.790 1.021 0.905
Spinal cord 0.002 0.002 0.002
Spleen 0.886 0.649 0.768
Stomach 0.044 0.047 0.046
Testes 0.064 0.054 0.059
Thymus 0.006 0.005 0.006
Thyroid 0.001 0.001 0.001
090177e195794698\Approved\Approved On: 09-Nov-2020 21:23 (GMT)
FDA-CBER-2021-5683-0014038